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ABSTRACT 
Novel oxovanadium(IV) complexes of glycine, ʟ-alanine, 1-methylimidazole-2-carboxylic 
acid, imidazole-2-caboxylic acid and imidazole-4-carboxylic acid  were synthesized and 
isolated in the solid state. The ligands and complexes were characterized by elemental 
analysis, melting point, NMR, IR and UV-vis spectroscopy. The IR studies showed that 
glycine and ʟ-alanine coordinate monodentately through the amine nitrogen whilst the 
imidazole-carboxylic acid derivatives assume a bidentate chelation. The electronic 
spectroscopic studies indicate distorted octahedral geometry for the oxovanadium complexes 
of amino acids and a square pyramidal geometry for oxovanadium(IV) complexes of 
imidazole carboxylic acid derivatives. 
The reaction of vanadyl (VO
2+
) with glycine, ʟ-alanine, imidazole-2-cabrboxylic acid, 
imidazole-4-carboxylic acid and 1-methylimidazole-2-carboxylic acid was studied in aqueous 
solution by pH-potentiometry under oxygen and carbon dioxide-free conditions. The data 
obtained from these titrations were used to calculate the protonation and stability constants. 
The results showed that all ligands are suitable for bidentate coordination in the formation of 
monomeric species although the solid state studies of the oxovanadium(IV) complexes of 
amino acids showed a monodentate coordination. The overall stability constants for the 
(V
IV
O)-ʟ-alanine system (log β120 = 18.27(6)), (V
IV
O)-glycine system (β120 = 17.22(6)), 
(V
IV
O)-imidazole-4-carboxyic acid (β120 = 11.38(8)), (V
IV
O)-imidazole-2-carboxylic acid 
(β120 = 11.62(6)) and (V
IV
O)-1-methylimidazole-2-carboxylic acid (β120 = 15.49(9)) were 
obtained. The calculations for the species distribution in the experimental pH range showed 
that the neutral bis-coordinated complexes are dominant over the biological pH range. 
 The glucose uptake effect of oxovanadium(IV) complex of ʟ-alanine, imidazole-4-
carboxylic acid, imidazole-2-carboxylic acid and 1-methylimidazole-2-carboxylic acid was 
investigated using 3T3-L1 adipocytes, Chang liver and C2C12 muscle cells at various 
concentrations. The compounds had significant glucose uptake on Chang liver cells only at a 
concentration of 0.1-10 µM whilst in the C2C12 muscle and 3T3-L1 cells the compounds 
showed little to no activity probably due to the lower concentrations employed as a result of 
the cytotoxicity of these compounds on these two cell lines. 
Keywords: diabetes mellitus, vanadium, amino acid, imidazole, stability constant, speciation. 
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CHAPTER 1 
INTRODUCTION 
1.1 Diabetes mellitus 
Diabetes mellitus is a chronic metabolic disorder that occurs either when the pancreas does 
not produce enough insulin or when the body cannot effectively use the insulin it produces. 
Insulin is a hormone that regulates blood sugar. The body of a diabetic patient does not 
produce or use the insulin necessary to stimulate the uptake of glucose, fatty acids and amino 
acids from the blood circulation for storage or utilization.
1
 For the function and survival of all 
organs, a continuous supply of the correct amounts of glucose is essential. Undersupply of 
glucose (hypoglycamia) leads to apoptosis (cell death) and oversupply (hyperglycaemia) 
leads to various organ damages. It is therefore necessary to maintain the physiological blood 
concentrations regulated at the optimal level of around 5 mM.
2
  
Apart from the intake of food, glucose may also be synthesized from lactate or alanine 
(gluconeogenesis). In all these processes insulin plays a central role, and its lack, insufficient 
supply or insufficient recognition by cell receptors causes the chronic disease diabetes 
mellitus. The lack of insulin causes uncontrolled degradation of fat since lipolysis is not 
inhibited and thus production of acetyl-coenzyme-A in amounts which can no longer be 
tackled by the citric acid cycle. As a consequence, ketonic bodies such as acetoacetic acid 
become the main factor responsible for severe damage of the peripheral blood vessels, 
creating extensive open wounds and necroses mainly at the limbs.
2
 Another typical symptom 
of diabetes mellitus is diabetic retinopathy, a severe damage of the view (blurred vision and 
blind spots) caused by destruction of the small blood vessels in the retina, finally leading to 
blindness. Other complications associated with diabetes are kidney failure, heart disease and 
neuropathy.
1
 
The first symptoms are related to the direct effects of high blood sugar levels. When the 
blood sugar level rises above 160 to 180 mg/dL, sugar spills into the urine.
2 
When the level of 
sugar in the urine rises even higher, the kidneys excrete additional water to dilute the large 
amount of sugar. People with diabetes urinate large volumes frequently (polyuria) since the 
kidneys produce excessive urine. The excessive urination creates abnormal thirst 
(polydipsia). Diabetic people lose weight because excessive calories are lost in the urine. To 
compensate for this, diabetic people often feel excessively hungry.  
2 
 
1.1.1 Forms of diabetes 
There are many types of diabetes that result from specific conditions such as maturity-onset 
diabetes of youth, surgery, medications, infections, pancreatic disease, and other illnesses.  
The most common forms of diabetes mellitus are classified as type 1 or type 2. Gestational 
diabetes is another form of glucose intolerance which is diagnosed during pregnancy. It is 
hyperglycemia with onset or first recognition during pregnancy and is common among obese 
women and women with a family history of diabetes. Immediately after pregnancy, 5% to 
10% of women with gestational diabetes are usually found to have type 2 diabetes.
3
 
(a) Type 1 
This type of diabetes was previously called insulin-dependent diabetes mellitus (IDDM) or 
juvenile-onset diabetes. It develops when the body’s immune system destroys pancreatic beta 
cells, the only cells in the body that make the hormone insulin to regulate blood glucose. This 
form of diabetes usually strikes children and young adults, although disease onset can occur 
at any age. In adults, type 1 diabetes accounts for 5% to 10% of all diagnosed cases of 
diabetes. Risk factors for type 1 diabetes mellitus may be autoimmune, genetic, or 
environmental.
1
 
The principal treatment of type 1 diabetes mellitus, even in its earliest stages, is the delivery 
of artificial insulin via injection combined with careful monitoring of blood glucose levels 
using blood testing monitors. Without insulin, diabetic ketoacidosis often develops which 
may result in coma or death. Treatment emphasis is now also placed on lifestyle adjustments 
such as diet and exercise although these cannot reverse the progress of the disease. Apart 
from the common subcutaneous injections, it is also possible to deliver the insulin by a pump, 
which allows continuous infusion of insulin 24 hours a day at preset levels and the ability to 
program doses of insulin as needed at meal times. An inhaled form of insulin was approved 
by FDA in January 2006, although it was discontinued for business reasons in October 2007.
1
 
Non-insulin treatments, such as monoclonal antibodies and stem-cell based therapies, are 
effective in animal models but have not yet completed clinical trials in humans.
3 
 
 
 
3 
 
(b) Type 2 
This type of diabetes was formerly called non-insulin-dependent diabetes mellitus (NIDDM) 
or adult-onset diabetes mellitus. It results from the body’s ineffective use of insulin. Type 2 
diabetes mellitus is mainly due to insulin resistance or reduced insulin sensitivity, combined 
with relatively reduced insulin secretion which in some cases becomes absolute. The 
defective responsiveness of the body tissues to insulin almost certainly involves the insulin 
receptor in the cell membranes. However, the specific defects are not known but the low 
receptor density is due to destruction by ketonic bodies. In the early stages of type 2 diabetes, 
the predominant abnormality is reduced insulin sensitivity, characterized by elevated levels of 
insulin in the blood. At this stage hyperglycaemia can be reversed by a variety of measures 
and medication that improve insulin sensitivity or reduce glucose production by the liver. As 
the disease progresses, the impairment of insulin secretion worsens and therapeutic 
replacement of insulin often becomes necessary. 
Type 2 diabetes mellitus comprises 90% of people with diabetes around the world, and is 
largely as a result of excess body weight and physical inactivity.
3
 Many people destined to 
develop type 2 diabetes spend many years in a state of pre-diabetes, a condition that occurs 
when a person’s blood glucose levels are higher than normal but not high enough for a 
diagnosis of type 2 diabetes. As of 2009 there are 57 million Americans who have pre-
diabetes.
1
 
1.1.2 Statistical epidemiology 
Diabetes mellitus is becoming a major health concern for low and middle income countries,
5
 
as well as developed countries. Currently, more than 6% of the population of developed 
countries are estimated to have diabetes.
4
 In underdeveloped countries, the many 
undiagnosed diabetic individuals make estimation difficult. World Health Organisation 
(WHO) estimates that more than 220 million people have got diabetes and the number is set 
to double by the year 2030.
5
 In 2005, an estimated 1.1 million people died from diabetes with 
a projected rise of 50% in deaths in 10 years time. Almost 80% of diabetes deaths occur in 
low and middle income countries and half of diabetes deaths occur in people under the age of 
70 years, with 55% of diabetes deaths being women.
5
 The greatest increase in prevalence is, 
however, expected to occur in Asia and Africa.
4
 The increase in incidence of diabetes in 
developing countries follows the trend of urbanisation and lifestyle changes, perhaps most 
importantly a “Western-style” diet. The severity of diabetes is illustrated by figure 1.1. 
4 
 
                                        
 
Figure 1.1: Population distribution map of people suffering from diabetes
5
 
1.1.3 Current therapy 
There is currently no practical cure for diabetes but it can be controlled. The fact that type 1 
diabetes is due to failure of the beta cells in the pancreas led to the study of several possible 
strategies to cure this form of diabetes either by replacing the pancreas or just the beta cells.
4
 
In 1921 Banting and Best isolated insulin and demonstrated its ability to lower blood glucose 
levels.
3
 However, with obesity frequently being the resulting cause of diabetes, the first 
approach in treatment should include a healthy diet and exercise plan that will lead to weight 
reduction.
6
 A diet alone is often not always sufficient for glycaemic control until it is coupled 
with anti-diabetic drugs and occasionally painful insulin injections.
7 
(a) Insulin
 
Insulin is the principal hormone that regulates uptake of glucose from the blood into most 
cells, primarily muscle and fat cells but not central nervous systems. Therefore the deficiency 
5 
 
of insulin or insensitivity of its receptors on cell membranes plays a central role in all forms 
of diabetes mellitus. Insulin is released into the blood by beta cells, found in the Islets of 
Langerhans in the pancreas, in response to rising levels of blood glucose, typically after 
eating. Insulin is used by about two-thirds of the body’s cells to absorb glucose from the 
blood for use as fuel, conversion to other needed molecules, or for storage. Insulin is the 
principal control signal for conversion of glucose to glycogen for internal storage in liver and 
muscle cells. Lowered glucose levels result both in the reduced release of insulin from the 
beta cells and in the reverse conversion of glycogen to glucose. This is mainly controlled by 
the hormone glucagon which acts in an opposite manner to insulin.
3
 Insulin is utterly 
necessary for controlling type 1 diabetes and the artificial form is usually derived from pork 
or beef. Insulin is often administered as a complex with protamine and zinc. This slows down 
its action, providing longer glucose control.
3
 
(b) Sulfonylureas
 
Sulfonylureas are a class of drugs that treat type 2 diabetes.
1 
The discovery of sulfonylureas 
was by chance. It was observed that certain sulphonamide antibacterials often resulted in 
hypoglycaemia and hence non-antibacterial sulfonylureas which reduced blood glucose levels 
were developed.
9 
These drugs only function by stimulating the release of endogenous 
reserves of insulin from the pancreas and are therefore only effective in patients who are still 
able to synthesize and secrete insulin.
3
 Examples of such drugs are glybenclamide and 
tolbutamide (see figure 1.2). Unfortunately, sulfonylureas do not always succeed in 
controlling diabetes. With sulfonylurea therapy, some 10% to 20% of type 2 diabetic patients 
immediately fail to control their blood glucose levels adequately on the highest recommended 
dose, a situation called “primary failure”.1 
Glybenclamide
Tolbutamide
 
Figure 1.2: Chemical structures of sulfonylureas 
6 
 
Sulfonylureas themselves tend to overwork the pancreas until it eventually “burns out” and is 
unable to secrete an adequate amount of insulin. Some 5% to 10% of patients who initially 
respond to sulfonylurea therapy subsequently fail to sustain the response each year, a 
situation called “secondary failure”. About 80% to 90% of people with diabetes are obese and 
sulfonylureas tend to make them gain weight. Sulfonylureas can also cause hypoglycemia, 
abnormally low blood glucose level, which posses its own dangers.
1
 The other side effects of 
sulfonylureas are the gastrointestinal distress, drowsiness, dizziness and skin reactions.  
(c) Biguanides 
It was found that a guanidine derivative lowered blood glucose levels in rabbits.
1
 This led to 
the development of phenformin and metformin that make muscle and fat cells more sensitive 
to insulin in the bloodstream, resulting in better glucose uptake. Unlike sulfonylureas, 
biguanides lower blood glucose levels without stimulating the release of insulin from the 
pancreas. The three proposed modes of action are
3
: 
1. inhibition of intestinal transport and absorption of sugars 
2. inhibition of gluconeogenisis at the liver 
3. effect metabolism in peripheral tissues by enhancing the uptake of glucose. 
 
NH
N
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phenformin metformin  
Figure 1.3: Chemical structures of biguanides 
The side effects of biguinides are weight loss, decrease in absorption of folic acid and vitamin 
B12, stomach pain and gastrointestinal effects such as anorexia, flatulence and metallic taste. 
(d) Thiazolidinediones 
Thiazolidinediones (TZDs), also known as glitazones, act on target tissues to decrease 
resistance of insulin. They bind to PRAY, a type of nuclear regulatory protein involved in 
transcription of genes regulating glucose and fat metabolism.
9
 Examples of glitazones are 
rosiglitazone (Avandia) and pioglitazone (Actos) (see figure 1.4). 
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Figure 1.4: Chemical structures of glitazones 
As a result of multiple retrospective studies, there is concern about rosiglitazone’s safety. 
Although it is established that this class of drugs has a beneficial effects on diabetes, there is 
concern about the increase in the number of severe cardiac events in patients taking it.
11
 The 
safety of rosiglitazone arose when a retrospective meta-analysis was published in the New 
England Journal of Medicine.
10 
There have been a significant number of publications since 
then, and a Food and Drug Administration panel
14
 voted (20:3) with some controversy that 
available studies supported a signal of harm and yet voted (22:1) to keep the drug on the 
market. The meta-analysis was not supported by an interim analysis of the trial designed to 
evaluate the issue, and several other reports have failed to conclude the controversy. This 
weak evidence for adverse effects has reduced the use of rosiglitazone, despite its important 
and sustained effects on glycaemic control.
12
 Safety studies are continuing. In contrast, at 
least one large prospective study has shown that pioglitazone may decrease the overall 
incidence of cardiac events in people with type 2 diabetes who have already had a heart 
attack.
13
 Some other adverse reactions of the glitazones are edema, anemia and weight gain. 
(e) Meglitinides 
Meglitinides lower blood glucose by stimulating the release of insulin from the pancreas. It 
achieves this by closing adenosine triphosphate (ATP)-dependent potassium channels in the 
membrane of the beta cells. This depolarizes the beta cells, opening the cells' calcium 
channels, and the resulting calcium influx induces insulin secretion.
1
 Examples of 
meglitinides are repaglinide (prandin) and nateglinide (starlix). 
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Figure 1.5:  Chemical structures of meglitinides 
Meglitinides are taken with or shortly before meals to boost the insulin response to each 
meal. If a meal is skipped, the medication is also skipped. The adverse reactions of 
meglitinides are weight gain and hypoglycemia. 
Several shortcomings are associated with all these type 2 drugs, therefore it is necessary to 
design new drugs with improved side-effect profiles. 
 
1.2 Vanadium in treatment of diabetes mellitus 
The investigation of the biochemistry of vanadium has only recently begun to catch up to that 
of its transition metal neighbours in the first row. Vanadium compounds are being considered 
for mitigating insufficient insulin response in diabetes mellitus. They cannot, however, 
entirely substitute for lack of insulin (as in type 1 diabetes) but can reduce reliance on 
exogenous insulin or perhaps substitute for other oral hypoglycaemic agents used in treatment 
of type 2 diabetes.
14-16
 Inorganic salts of vanadium have shown promising insulin-enhancing 
effects but the potential toxicity of vanadate and low absorption rate of vanadyl sulfate have  
pushed the focus towards designing new organovanadium compounds.
17,18
 In the 
development of oral anti-diabetic drugs, tailoring of the properties of these vanadium 
complexes can be achieved by simple modification of the organic carrier ligand. 
Vanadium is by no means the only metal that has therapeutic effects for the treatment of 
diabetes mellitus. Metals or minerals which have anti-oxidant status such as copper, 
manganese, zinc and selenium exhibit increased sensitivity to insulin.
19
 However, the 
American Diabetes Association does not recommend supplementation of metals by patients 
with diabetes due to a possibility of them becoming pro-oxidant at higher doses and only 
recommends supplementation in the form of dietary habits to include food richer in metals. 
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The role of chromium in glucose metabolism has also resulted in the marketing of chromium 
as a nutritional supplement with chromium picolinate being available over the counter in a 
form of pills, sports drinks and nutrition bars.
19  
The interest in vanadium chemistry was initiated by the discovery that the vanadate ion was a 
potent inhibitor of protein tyrosine phosphatases.
20 
Vanadium has been implicated in 
performing many functions of insulin such as inhibition of lipolysis and gluconeogenesis as 
well stimulating lipogenesis and cellular glucose uptake, hence its compounds are referred to 
as insulin-mimetics.
2,21,22
 Several vanadium compounds seem to have insulin-enhancing 
effects due to their ability to mediate signal transduction downstream of the insulin signalling 
pathway through post-insulin receptor kinase mechanism (by inhibiting phosphatases).
23
 The 
following section will briefly describe a selected few of such compounds. 
1.2.1 Anti-diabetic vanadium compounds 
In 1897-98, aqueous solutions of sodium vanadate were tested with respect to vanadium’s 
possible benefits in the treatment of 44 test subjects with various health problems including 
anemia, tuberculosis, rheumatism, arnyotrophia, hysteria, neurasthenia and diabetes.
24
 The 
test subjects were treated orally over 24 hours, and three times per week, with 4-5 mg of 
Na[VO3] dissolved in water prior to meals. All the patients showed an increase in appetite, a 
gain in weight, and an improvement in their physical status. For the diabetic patients, a slight 
decrease in blood sugar was observed for two out of three patients. This was the first report 
on the possible benefits of vanadate in the treatment of diabetes mellitus.
25
 The medication of 
humans with vanadate has been resumed only sporadically, probably due to the toxicity of 
vanadate in non-physiological doses.
2
 The in vivo effects of vanadate in streptozotocin 
(STZ)-induced diabetic rats was first reported by Heyliger et al
26
 and Meyerovitch et al.
 27
 
Vanadyl sulfate was shown to have comparable effects in STZ rats.
28
  Vanadyl sulfate is 
advantageous over vanadate because it is sufficiently less toxic but its disadvantage is its low 
rate of absorption in the gut, estimated to be less than 1% of the dose. The unsatisfactory 
absorption is due to the formation of insoluble vanadyl hydroxides under the slightly alkaline 
conditions (see section 1.3.3) in the small intestine. 
The potential toxicity of vanadate and the very low absorption rate of the less toxic vanadyl 
sulfate also exclude these inorganic salts from potential use as anti-diabetic drugs. As an 
alternative, vanadium coordination compounds containing organic ligands have been 
developed and tested. It is important that these ligands should not pose a threat to the body 
10 
 
once cleaved from the vanadium ion in the bloodstream since these are prodrugs and the 
necessary metabolite is vanadium in a form of vanadate. The successful vanadium complexes 
contain organic ligands that are reasonably soluble in both organic and aqueous environments 
and which are compatible with human metabolism. The recent successes achieved with 
organo-vanadium complexes suggest that modification of the metal ion chemistries by the 
organic ligands not only increased absorption and therefore efficacy but also decreased 
toxicity.
29
 As oral anti-diabetic drug candidates all the vanadium complexes should have the 
desirable properties of an oral drug namely low molecular weight, water solubility, balanced 
lipophilicity and/or hydrophility, neutral charge and thermodynamic stability. Among others, 
the following organo-vanadium compounds have been studied extensively. 
(a) Bis(maltolato)oxovanadium(IV) and bis(ethylmaltolato)oxovanadium(IV) complexes 
Bis(ethylmaltolato)oxovanadium(IV) (BEOV) was first synthesized in the late 1990s, as one 
in a series of compounds containing maltolato ligand variants. BEOV and BMOV (figure 1.6) 
consist of a vanadyl ion bound to the anion of ethylmaltol (3-hydroxy-2-ethyl-4-pyrone) and 
maltol (3-hydroxy-2-methl-4-pyrone) respectively. An interest in maltol, a flavoring agent to 
baked foods and some beverages, is partly due to its ability to deprotonate readily for the ease 
of coordination to the vanadyl ion and for its non-toxicity. 
O
O
R
O
O
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R = CH3           BMOV
R = C2H5          BEOV
 
Figure 1.6: Chemical structures of BMOV and BEOV 
BMOV is the most widely and intensively tested of the many proposed insulin mimetic 
vanadium complexes.
30
 In addition to lowering glucose and lipid levels in vivo BMOV delays 
or prevents long term diabetes-induced pathology (including cardiomyopathy) and attenuates 
hyperinsulinemia and hyperlipidemia in genetically diabetic rats.
30
 BEOV passed Phase I 
clinical trials where safety and tolerability of single escalating doses of orally administered 
10 mg, 25 mg, 35 mg, 60 mg and 90 mg single doses were confirmed in non-diabetic 
volunteers.
15
 BEOV is the only vanadium compound that has passed Phase II clinical trial 
where safety and efficacy was assessed in type 2 diabetic volunteers.
15
 The overall 
bioavailability of vanadium from BMOV and BEOV was 2-3 times that from vanadyl 
sulfate.
15
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(b) Bis(picolinato)oxovanadium(IV) complex 
Several oxovanadium(IV) complexes with a VO(N2O2) chromophore have been proposed as 
insulin-enhancers. One example is bis(picolinato)oxovanadium(IV), VO(pic)2, the synthesis 
of which was reported in 1964
31
 but which was only recently characterized structurally and 
tested biologically.
32 
N
O ON
OO
V
O
 
Figure 1.7: Chemical structure of bis(picolinato)oxovanadium(IV) ([VO(pic)2]) 
The insulin-enhancing effects of picolinato chelates of oxovanadium(IV) have been clearly 
shown to be dependent on dose as well as delivery method. When [VO(pic)2] was admitted 
orally to STZ-induced diabetic rats  (0.2 mmol.kg
-1
 for 2 days followed by 0.1 mmol.kg
-1
 for 
11 days), plasma glucose levels normalised while plasma insulin levels increased.
31
 However, 
when administered as a solution (2.4 mM), as a substitute for drinking water, only glucose-
lowering tendencies and not insulin-elevation was observed. The latter method was also 
accompanied with signs of gastrointestinal irritation.
31
 On the other hand, comparing 
[VO(pic)2] with BMOV,
32
 the picolinate complex had lower solubility and more 
gastrointestinal irritation for an equivalent dose, suggesting that there is room for further 
structural improvement in order to increase bioavailability and lessen side effects. 
(c) Bis(pyridinonato)oxovadium(IV) complex 
1,2-dimethyl-3-hydroxy-4-pyridinone (dhp) is an acetogenin which occurs as a fungal 
carbohydrate metabolite and can be produced as a byproduct of fermentation. Like maltol, 
hdp can selectively alter the water-solubility, hydrolytic stability and lipophilicity of its metal 
complex.
31
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Figure 1.8: Chemical structure of VO(dhp)2 complex 
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VO(dhp)2 demonstrated its insulin-mimetic action in glucose uptake by primary isolated rat 
adipocytes and its capacity to inhibit free fatty acids release from these cells.
33
 In fact, it 
presents a relevant inhibitory effect on lipolysis. Moreover it was found that it promotes total 
protein tyrosine phosphorylation, an evidence that this protein of the insulin signalling 
cascade is a target for its action. Thus VO(dhp)2 appears as a promising candidate for the 
treatment of diabetes. 
1.2.2 Mechanism of action of vanadium 
The true form of the necessary vanadium species under physiological conditions is a subject 
of much debate but a focal mechanism of action which seems to enjoy a broad consensus is 
its involvement in the inhibition of phosphate-metabolizing enzymes.
2,21,22
 The action of 
vanadium at an intracellular level is due to the structural similarity between phosphate and 
vanadate. Once the vanadium compounds are in the blood they may dissociate and vanadium 
is shuttled by proteins such as transferrin in the vanadate form (H2VO4
-
) which is the species 
involved in the mechanism explained in figure 1.9.    
Scenario I: Describes the situation prior to docking of insulin (In) to its receptor (IR). 
Scenario II: Docking of insulin to the outside (α subunit) of its receptor leads to 
phosphorylation of tyrosine at the inside β subunit of the receptor, which initiates the 
phosphorylation of IRS. Phosphorylation of IRS in turn induces a signal transduction (zigzag 
arrow) by which Glut 4 is translocated to the membrane thereby internalising glucose (curved 
arrow). Glucose is either oxidized, metabolized to triglycerides or used up in glycogen 
synthesis.  
Scenario III: In the absence of insulin, or in the case of a lack of insulin response (type 2 
diabetes), autophosphorylation of the β subunit is counteracted by a protein tyrosine 
phosphatase (PTP), annulling the phosphorylation of IRS and thus the signal transduction 
(broken lines). 
Scenario IV: Vanadium enters the cell by diffusion, endocytosis or via ion channels, such as 
phosphate channels (P/VCh) in the case of the vanadate, inhibiting the phosphatase and thus 
re-establishing signal transduction. Vanadate binds tightly in the active site of phosphatases 
forming hydrogen bonds with OH-, SH-, or N- functional amino acid side chains, and thus 
prevent phosphatases from hydrolyzing IRS and there is a crystal structure evidence of this 
interaction.
44
 It has also been shown that wortmannin, a classical suppressor of insulin-
13 
 
signaling activities, does not suppress IR and IRS phosphorylation stimulated by vanadium 
(or vanadium and insulin), providing evidence that vanadium compounds exert their activity 
at an early stage.                    
 
Figure 1.9: Mechanism of the stimulation of glucose uptake by insulin or vanadate.
2
 
In=insulin; IR=insulin receptor; P/VCh=anion channel for phosphate and vanadate; Glu= 
glucose; Glut 4 = glucose transporter 4; PTP = protein tyrosine phosphatase; IRS = insulin 
receptor substrates 
 
1.3 Vanadium chemistry 
Vanadium was named after Vanadis, the Scandinavian goddess of beauty, due to its display 
of colours in the different oxidation states, for example, +5 is yellow, +4 is blue, +3 is green 
and +2 is lavender.
2
 Vanadium has an electronic configuration of [Ar]d
3
4s
2
 in the ground 
state and can exist in eight oxidation states ranging from -3 to +5 but with the exception of -
2.
34
 Only the three highest oxidation states, +3, +4 and +5, are important in biological 
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systems.
36-38
 The element was initially thought to have been discovered in 1801 by A.M del 
Rio in a sample of Mexican lead ore. He later withdrew his claim when it was incorrectly 
suggested by his peers that the sample he found was in fact lead chromate. In 1830, N.G 
Sefström rediscovered it in Swedish iron ore.
8
  
Vanadium, element number 23 of atomic weight 50.94, is present at very low concentrations 
in plant and animal cells.
39
 This transition metal is relatively abundant (~0.02%) in nature. 
Under physiological conditions it exists predominantly in the anionic form ([H2VO4]‾) with 
the oxidation state +5, or in the +4 oxidation state as the vanadyl cation (VO
2+
). As with the 
other metal ions in biological systems vanadium is primarily complexed in vivo. In mammals, 
approximately 90-95% of the circulating vanadium in the bloodstream (32-95 pg/ml) is 
associated with plasma components such as transferrin, albumin and hemoglobin, as well as 
low molecular weight compounds such as glutathione.
40
 It is believed to be nutritionally 
essential in mammals, but its specific biological use in humans is still to be elucidated. 
However, the total body pool of vanadium in humans is approximately 100-200 µg,
39
 
suggesting some importance. 
1.3.1 Redox chemistry 
The one-electron redox reactions for the three oxidation states of relevance are represented by 
the equations below.
2
 
V
V
O2
+
 + 2H
+
 + e
- 
 V
IV
O
2+
 + H2O      
[H2V
V
O4]
- 
+ 4H
+
 + e
-
  V
IV
O
2+
 + 3H2O      
V
IV
O
2+
 + 2H
+
 + e
-
  V
3+
 + H2O      
Table 1.1: Redox potentials for inorganic vanadium species and selected physiological 
systems versus the normal hydrogen electrode (NHE).
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Species E
o
 E
pH=7
 
VO
2+
/V
3+
 +0.359 -0.462 
H2VO4
-
/VO
2+
 +1.31 -0.34 
VO2
+
/VO
2+
 +1.016 +0.19 
O2/H2O2 +0.695 +0.295 
O2/H2O +1.23 +1.23 
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Table 1.1 reveals that, under aerobic conditions V
V
 is stable whereas in anoxic environments, 
which normally prevail in the cytoplasm reducing agents such as ascorbate and glutathione 
readily reduce V
V
O2
+
 to V
IV
O
2+
, provided that the inorganic species are available as such, i.e. 
not complexed to ligands  present in the intra- and extracellular fluids. Vanadate ([H2VO4]‾) 
is less readily reduced, and the reduction of V
IV
O
2+
 to V
3+
 does not take place under common 
conditions. V
III
 is therefore of minor importance when it comes to physiological actions of 
vanadium, with the exception of ascidians and Polychaeta fan worm systems where this 
oxidation state is the predominant one.
2
 
1.3.2 Coordination chemistry 
The coordination numbers of 5 and 6 are the most common in oxovanadium(IV) complexes, 
based on the VO
2+
 moiety.
41
 Independent of the oxidation state, the coordination geometry 
for the five coordinate compounds is commonly square pyramidal, usually slightly distorted. 
The trigonal bipyramidal arrangement is less frequent. Typical bi- to tetradentate ligands used 
for the stabilization of the oxo- and dioxovanadium centers contain the O-donors (phenolate 
and carboxylate) and the N-donors (aromatic and aliphatic amines, and imine nitrogens). 
The chemistry of the square pyramidal geometry has been well established with the oxygen 
of the oxovanadium(IV) unit in the apical position and the vanadium atom lying above the 
plane defined by the donor atoms of the four equatorial ligands. These square pyramidal 
complexes generally exhibit a strong tendency to remain five coordinate.
42
 However, orange 
polynuclear linear chain structures (…V=O…V=O…) have been observed with 2-(2’-
hydroxylphenyl)benzoxazole and 2(2-hydroxyphenyl)bezothiozole, as ligand.
42-45
 The 
absorption band due to V=O stretching vibration of oxovanadium(IV) is usually observed at 
higher wavenumber compared to those of vanadate complexes. The V=O stretching vibration, 
however, is susceptible to a number of influences including electron donation from basal 
plane ligand atoms, solid state effects, and coordination of additional solvent molecules. 
1.3.3 Solution chemistry 
A vanadium complex that is to be used as an orally-administered drug for lowering glucose 
levels, must be thermodynamically stable in both acidic and neutral environments.
47
 This 
stability is required because the vanadium complex must survive the digestion process in the 
stomach where the pH can be as low as 2.0, and must also remain intact under pH condition 
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of the intestines and be delivered into the bloodstream where the pH is 7.4. The determination 
of the thermodynamic stability of the vanadium complexes as a function of pH is a 
prerequisite for evaluating the usefulness of such complexes to serve as glucose-lowering 
drugs. It is therefore important to understand the aqueous chemistry of vanadium in order to 
design the correct ligands for the stabilization of vanadyl ions. 
Acidification of vanadate(V) solutions yields yellow solutions of decavanadate, [HnV10O28]
6-n
 
(n=0-3, depending on the pH) or for pH<2, the colourless hydrated dioxovanadium 
monocation, [VO2(H2O)4]
+
. If these V
V
-containing solutions are reduced, gradual formation 
of vanadyl V
IV
O
2+
 (blue), V
3+
 (green) and V
2+
 (violet) occurs, again existing in the form of 
the aqua cations. V
2+
 is not stable in aqueous media, it is rapidly reoxidised to V
3+
 by protons. 
In aqueous solutions containing the V
3+ 
the following octahedral species, depending on pH 
and concentration, can be present; [V(H2O)6]
3+
, [V(OH)(H2O)5]
2+
, [V(OH)2(H2O)4]
+
 and 
[{V(H2O)5}2(µ-O)]
4+
. The only vanadium oxidation states relevant to the biological systems 
are +3, +4 and +5. At concentrations less than 1 nM, the oxo-bridged dinuclear complex can 
be neglected.
2
 The equations below
47 
show the acid-base equilibria of the mononuclear V(III) 
species. 
[V(H2O)6]
3+
 + H2O   [V(OH)(H2O)5]
2+
+ H3O
+
                                          (pKa1=2.7)                     
[V(OH)(H2O)5]
2+
 + H2O   [V(OH)2(H2O)6]
+
 + H3O
+
                                (pKa2=4.0)    
   
The presence of sulfate in acidic solutions of V
3+
 leads to the formation of aqua-sulfato 
complexes which is of interest in the light of the conditions in the vanadium containing blood 
cells of ascidians.
48 
 [V(SO4)(H2O)5]
+
+ H2O   [V(SO4)(OH)(H2O)4] + H3O
+
                           (pKa=3.35) 
  
In contrast to V
III
, V
IV
 forms monooxo complexes in aqueous media, based on the stable 
vanadyl ion, VO
2+
.  The vanadyl ion remains in solution only under sufficiently acidic 
conditions as shown below.
2
 
[VO(H2O)5]
2+
 + H2O   [VO(OH)(H2O)4]
+
 + H3O
+
                                     (pKa=6.0)      
2[VO(H2O)5]
2+
 + 2H2O   [{VO(H2O)4(µ-OH)}2]
2+
 + 2H3O
+
                    (pKa=6.9)              
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Precipitation of insoluble hydroxide, VO(OH)2, (see equations below) and formation of 
oligonuclear hydroxo species such as {[(VO)2(OH)5]‾}n begins above pH 5. Concomitantly, 
[VO(OH)3]‾  starts to be present at nanomolar concentrations, gaining importance at pH 10 
and above. 
[VO(OH)(H2O)4]
+
 + H2O    H3O
+ 
+ [VO(OH)2(H2O)3]=VO(OH)2   
VO(OH)2 + OH‾   [VO(OH)3]‾       
All vanadium(V) species present in water at ambient pH are anionic. The cationic VO
3+
 and 
VO2
+
 exist only when they are stabilised by ligands.  At pH 7, the diprotonated forms 
[H2VO4]‾
  
(pKa=8.17) and [H2V2O7]
2‾ (pKa=8.50) for physiological ionic strength 
predominate. As far as monovanadate is concerned, this is of interest in the context of its 
similarity with phosphate which, at pH 7, is present mainly in its monoprotonated form, i.e. 
[HPO4]
2‾ (pKa of [H2PO4]‾
 
= 6.7). In the medium to strong alkaline range, only mono- and 
divanadate exist. On acidification, decavanadate forms starting at pH 6. Below pH 3, 
decavanadate becomes unstable and [VO2(H2O)4]
+
 begins to form and below pH 2 this is the 
only cationic species that can exist.
48
 Although thermodynamically unstable above pH 6, 
decavanadate breaks down slowly in the mildly alkaline region to form lower nuclearity 
vanadates.  
Ligands such as maltol, ethylmaltol, picolinic acid and 1,2-dimethyl-3-hydroxy-4-pyridinone 
have been used to stabilize vanadium under aqueous conditions. The stability of these 
complexes in aqueous medium and under physiological conditions enables the vanadium to 
be shuttled from the stomach via the intestines into the bloodstream. The pH-metric chemical 
speciation of the vanadium compounds can be appropriately designed through the correct 
combination of donor atoms involved in the bidentate coordination of the ligands in order to 
achieve the requisite stabilization under the physiological pH range. The imidazole-
carboxylic acids and amino acids are simple ligands which have been used in this work for 
testing the ability of (N,COO‾) donor set for stabilizing VIVO. 
 
1.4 Biospeciation of vanadium 
Long-term supplementation with vanadium revealed that vanadium is stored in several organs 
including the liver, kidney, spleen, bone, heart and muscles.
49
 The main source of vanadium 
18 
 
is from food (e.g  mushrooms, fish, black pepper, fresh fruits and parsley), even though most 
foods contain low quantities (< 1 ng.g
-1
).
50
 Vanadium is poorly absorbed in living systems, 
with only less than 1% of an oral dose being absorbed in the gastrointestinal tract.
31
 The 
absorption, distribution, metabolism and excretion of vanadium compounds has been 
summarised schematically in Figure 1.10. Both anionic and cationic forms of vanadium have 
been detected in the bloodstream and both can penetrate the intracellular space by means of 
passive diffusion. Vanadium speciation in the blood is a vital process that determines what 
form of vanadium will enter the cells. Therefore determining what form the vanadium enters 
the bloodstream in and what form it takes upon interacting with blood serum proteins is vital 
in understanding the insulin-enhancing action of vanadium drugs. 
        
Figure 1.10: A schematic diagram showing the metabolic fate of oxovanadium compounds
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In the bloodstream vanadium comes into contact with high molecular mass (HMM) and low 
molecular mass (LMM) proteins. Complexation occurs with the blood proteins which 
facilitates cellular uptake. The two main HMM proteins are known as human transferrin (hTf) 
and human serum albumin (HSA). When hTf is loaded with an ion and it comes into contact 
with a receptor specific for hTf on a cell wall, hTf binds to that receptor. The hTf is taken 
into the cell by means of a vesicle where the internal pH of the vesicle is reduced by means of 
a hydrogen ion pump.
51 
Human serum albumin (HSA) is the most abundant protein in the 
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blood and has a variety of functions including the transport of various hormones and the 
transport of drugs.
52
 HSA also interacts with vanadium species in the blood.  
Studies
53,54
 using blood circulation monitoring-electron paramagnetic resonance (BCM-EPR) 
have shown that the majority of vanadium in the blood binds to hTf (approx 77%), therefore 
it is safe to designate hTf as the primary transport protein for vanadium. It has also been 
shown that hTf can bind the metal ion far more strongly than HSA despite the fact that HSA 
is the most abundant HMM serum protein. Results from both CD and EPR spectroscopic data 
show that complexation occur between hTf and V
IV
O and that the reactions result in ternary 
complexes.
53
 The ternary complexes are in the form; (V
IV
O)hTf(L), (V
IV
O)2hTf(L)2 and 
(V
IV
O)2hTf(L), where L is a bidentate carrier ligand. Figure 1.11 shows some proposed 
equilibria and ternary complexes of V
IV
O formed with serum proteins and carrier ligands in 
the blood serum.
53
 The strength of the bond between VO
2+
 and the carrier ligand play a role 
in the speciation within the blood. 
(1) (V
IV
O)apoTf(L) + L  apoTf + V
IV
OL2 
(2) (V
IV
O)2apoTf(L)2 + A  (V
IV
O)apoTf(L) + V
IV
OL2 
(3) (V
IV
O)2apoTf(L) + L  (V
IV
O)apoTf + V
IV
OL2 
apoTf
+VIVO2+ (VIVO)apoTf (V
IVO)2apoTf
+VIVO2+
(VIVO)apoTf(L)
+L
+L +V IV
O 2+
+VIVO2+
(VIVO)2apoTf(L)
+L +V IV
O 2+
+L
(VIVO)2apoTf(L)2
+L +V IV
O 2+
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Figure 1.11: Various equilibra proposed for the formation of ternary complexes of V
IV
O with 
serum bioligands and carrier ligands (L) 
The design of the organovanadium complexes should meet optimum conditions. The 
thermodynamic stability should not be weak because the complexes decompose before 
transportation into the blood circulation and it should not also be too strong because the 
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complexes should be able to dissociate to accommodate ligand substitution by bioligands 
(bL) and redox reactions. Figure 1.12 shows a simplified flow diagram of interactions 
between the absorbed vanadium prodrug, whether its carrier ligands are weak (for example 
picolinic acid), intermediate (for example maltol) or strong (for example dph), and the HMM 
and LMM serum proteins. The formed adducts are listed as well as their concentrations in 
comparison to each other.
54,55 
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Figure 1.12: Speciation model of insulin-enhancing compounds of the type VO(carrier)2, in 
the blood 
The various studies mentioned have all had specific results in terms of the drugs that were 
tested, however similarities are indeed present, for example, all studies that dealt with the 
[VO(carrier)2] solid 
[VO(carrier)2] in solution 
[VO(carrier)2]/[VO(carrier)]
+
 
(VO)2hTf (high) 
[VO(carrier)2]  
(intermediate or low) 
VO-hTf-bL (low) 
VO-hTf-carrier (low) 
[VO(carrier)(bLH-1)]
x-
 
(low) 
VO(carrier)2(HAS) 
(low) 
 
 
(VO)2hTf (high) 
VO-hTf-bL (low) 
(VO)2 HSA (very low) 
[VO(carrier)2] (intermediate) 
VO(carrier)2(HSA)(intermediate) 
VO(carrier)2(hTf) (intermediate) 
(VO)2hTf (low or intermediate) 
VO-hTf-bL (low) 
 
       Target cells 
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binding of vanadium to hTf concluded that this HMM protein is the primary binder of 
vanadate in serum. This conclusion was apparent each time despite the more abundant HMM 
protein HSA. Different conclusions have been reached about whether or not (VO)-HSA 
adducts should be considered negligible. The key question is whether or not albumins’ high 
concentration in the serum compensates for its weaker affinity for binding VO
2+
.  
There has, however, not been a study which relates the binding affinity of the carrier ligand to 
vanadium to the activity of these vanadium metallopharmaceuticals nor has there been a 
study that investigates the necessary therapeutic amounts of vanadium also in relation to the 
stability of the complexes. But these two abovementioned gaps as well as the biospeciation 
are deemed outside the scope of this investigation.  
 
1.5 Objectives of the study 
1. The synthesis of V(IV)  complexes using amino acid derivatives as possible anti-diabetic 
pharmaceuticals will be carried out. The current prescription drugs (based on organic 
compounds) that are being used have toxic side effects including nausea, diarrhea, skin 
rash, weight gain, respiratory infections, liver damage and headache. Hence there is need 
for an alternative class of drugs that devoid these side effects. Inorganic salts of vanadium 
have shown promising insulin-enhancing effects but the potential toxicity of vanadate and 
low absorption rate of vanadyl sulfate have pushed the focus towards designing new 
organovanadium compounds.
17,18
 The amino acids have been chosen as ligands because 
they are non-toxic biological molecules and the imidazoles are also found in many 
biological systems. 
2. The thermodynamic stability of the vanadium(IV)-amino acid derivatives will be 
determined over a pH range of 2 to 11 using potentiometric acid/base titrations and 
HYPERQUAD to calculate the stability constants. Vanadium complexes that are to be 
used as orally-administered drugs for lowering glucose levels must be thermodynamically 
stable in both acidic and neutral environments.
47
 This stability is required because the 
vanadium complex must survive the digestion process where the pH can be as low as 2.0 
and must be delivered into the bloodstream where the pH is 7.4. 
3. The species distribution diagrams will be generated in order to evaluate the species 
existing over the biological pH range. The species distribution plots of % vanadium as a 
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function of pH are important for evaluating the usefulness of such complexes to save as 
glucose lowering drugs.  
4. The biological studies will be performed to determine the cytotoxicity and the glucose 
lowering effect of the synthesized vanadium complexes. The cytotoxicity and glucose 
uptake of the synthesized vanadium complexes will be studied using three primary cell 
culture lines, i.e muscle (C2C12), fat (3T3-L1) and liver (Chang) cells. 
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CHAPTER 2 
EXPERIMENTAL TECHNIQUES AND METHODS 
 
2.1 Instrumentation 
The infrared spectra were recorded on a Perkin Elmer 400 FTIR spectrophotometer in the 
mid range (4000-400 cm
-1
) as KBr pellets or as neat solids using a Perkin Elmer 100 ATR-
FTIR. 
1
H and 
13
C NMR spectra were recorded on a Bruker AMX 400 NMR MHz 
spectrophotometer and results reported relative to tetramethylsilane (δ 0.00). Melting points 
were done using Gallenkamp Melting point apparatus equipped with a thermometer (0-400 
o
C). The vanadium content was determined using a Thermo Electron (iCAP 6000 Series) 
inductively Coupled Plasma (ICP) spectrophotometer equipped with an OES detector. 
Chromatographic separations were done on an Agilent 1100 High Performance Liquid 
Chromatograph (HPLC) fitted with a DAD detector and a Gemini C18 (100 mm x 4.6 mm x 
5 µm) column. Solid reflectance spectra were recorded on the Shimadzu UV-3100 UV-vis-
NIR spectrophotometer (1000-250 nm) fitted with a MPCF-3100 sample compartment. The 
samples were mounted between two quartz discs which fitted into sample holder coated with 
BaSO4. Microanalysis was carried out using a Vario Elementar Microcube ELIII. 
Potentiometric studies were performed using a Metrohm 794 Basic Titrino equipped with 
tiamo version 1.2 and Metrohm LL electrode. The pH measurements were done using a 
Metrohm 827 pH lab meter. Analytical weights were measured on a Sartorius Micro 
electronic microbalance. A Bio-Tek KC4 powerwave XS microtiter plate reader was used to 
measure absorbance for 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT) and for the glucose assay. 
 
2.2 Characterization techniques 
The oxovanadium(IV) complexes were characterized by using a wide variety of techniques 
including, but not limited to UV/Vis spectroscopy, infrared spectroscopy, microanalysis and 
ICP-OES analysis for the vanadium content.   
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2.2.1 ICP-OES analysis 
Inductively coupled plasma optical emission spectrometry (ICP-OES), also referred to as 
inductively coupled plasma atomic emission spectroscopy (ICP-AES), is an analytical 
technique used for the detection of trace metals. It is a type of emission spectroscopy that 
uses the inductively coupled plasma to produce excited atoms and ions that emit 
electromagnetic radiation at wavelengths characteristic of a particular element.
1,2
 The 
intensity of this emission is indicative of the concentration of the element within the sample. 
The intensities of all wavelengths (within the system's range) can be measured 
simultaneously, allowing the instrument to analyze for every element to which the unit is 
sensitive all at once. Thus, samples can be analyzed very quickly. The intensity of each line is 
then compared to previously measured intensities of known concentrations (standards) of the 
elements, and their concentrations are then computed by interpolation along the calibration 
lines. The strength of the ICP-OES technique is that many elements (up to 70) can be 
determined simultaneously in a single sample analysis but its limitation is that the emission 
spectra are complex and inter-element interferences are possible if the wavelength of the 
element of interest is very close to that of another element.
2
 In our case, only single-element 
analysis was carried out to determine the vanadium content in the vanadium complexes.  
Table 2.1: ICP-OES method and operating parameters 
Parameter Setting 
Plasma Ar gas Flow rate 5.0 L/min 
Auxiliary Ar gas flow rate 1.00 L/min 
Nebulizer Ar gas flow rate 0.90 L/min 
Sampling depth 8.5 mm 
Pump rate 100 rpm 
N2 addition flow rate 0.5 L/min 
Cooled spraying chamber temperature 4 
o
C 
Selected wavelength 292.4 nm 
Sample flush time 30 s 
Points per peak 3 
Time scan acquisition 50 ms/point 
RF power 1150 W 
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2.2.2 UV-vis spectrometric studies 
The UV-vis spectrophotometric technique was used to characterize the geometric structure of 
oxovanadium(IV) complexes. Vanadium compounds exhibit a multitude of stereochemical 
arrangements (figure 2.1), with V(V) complexes being found in tetrahedral, octahedral, 
trigonal and pentagonal bipyramidal geometries. V(IV) exhibits fewer geometries due to its 
rigidity, and  mainly square pyramidal, trigonal bipyramidal and distorted octahedral (if a 
sixth position is occupied) complexes are found.
3
 
octahedral square pyramidaltrigonal bipyramidaltetrahedral pentagonal bipyramidal
 
Figure 2.1: Some typical geometry of vanadium compounds 
Ballhausen and Gray,
4
 considered VO
2+
 in an aqueous solution as the [VO(H2O)5]
2+
 
molecular ion to elucidate the molecular orbital description of the vanadyl ion. They 
proposed that the vanadium 3d, 4s, and 4p orbitals, along with the 2s, 2pσ (2pz) and 2pπ (2px, 
2py) oxide oxygen orbitals, and the spσ hybrid oxygen (from water) orbitals were involved in 
bonding. The possibility of π-bonding of water oxygens was regarded as unlikely. The 
bonding strengths were arranged in the order (oxide oxygen) > (four square planar waters) > 
(axial water). With this in consideration, one can predict the following (symmetry in 
parenthesis): 
 A strong σ bond between the spσ oxygen hybrid orbital and the (4s + 3dz2) vanadium 
hybrid orbitals (a1) 
 Two π-bonds between the oxygen 2px and 2py orbitals and the vanadium 3dxz and 3dyz (e) 
 Four σ bonds between spσ orbitals of the water oxygens and the vanadium (4s-3dz2) (a1), 
4px and 4py (e), and 3dx2-y2 (b1) orbitals 
 The axial water oxygen is bonded to the remaining 4pz (a1) orbital 
 The vanadium 3dxy (b2) is non-bonding 
 
From this information, the energy level scheme was predicted for this d
1 
system and is shown 
in figure 2.2. McGlynn proposed, using a ligand field approach, that the π-bonding of the 
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equatorial ligands should not be neglected.
5
 This consideration only affects the order of the 
b1* and eπ*, however these energy levels are so close together that the inversion might occur 
between different complexes.
6
 This model predicts the following three transitions for the C4v 
symmetrical VO
2+
 molecular ion:  
b2  eπ
*
 (
2
B2  
2
E) 
b2  b1
*
(
2
B2  
2
B1) 
b2  I a1
* 
(
2
B2  
2
A1) 
 
 
Figure 2.2: Molecular orbital scheme for the VO
2+ 
species as outlined by Ballhausen and 
Gray
4
  
Bands appearing at a lower wavelength than 200 nm are assumed to be charge transfer. The 
lowering of symmetry from C4v to C2v usually has little or no effect on the observed spectra, 
since the splitting of the eπ* level is too small to be observed experimentally most of the 
time.
4
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The Ortolano, Selbin and McGlynn (OSM) scheme also predicts three visible transitions from 
the ground state, b2 (dxy). These include; dxy → (dxz, dyz); dxz→ (dx2 – y2) and dxz→ (dz2) as 
shown in figure 2.3. The first two transitions may invert depending on the σ-donor strength of 
the ligands. The third transition may overlap or be completely occluded by charge transfer 
bands. The difference in the field strength of the equatorial ligands may also cause the doubly 
degenerate eπ to split, resulting in four electronic transitions observed. The insertion of a sixth 
ligand on the axial position would not be expected to lead to any noticeable effects from the 
square pyramidal (C4v) geometry.
7
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Figure 2.3: Clustered energy level schemes for C4v and D3h symmetries in oxovanadium(IV) 
complexes
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2.3 Chemical speciation modeling 
Chemical speciation describes the composition (i.e. types and concentration of chemical 
compounds) of a solution.
8
 Speciation analysis is the analytical activity of identifying and 
measuring the quantities of one or more individual chemical species in a sample. The concern 
in this work is molecular speciation and not the oxidation state of vanadium species since the 
solution studies are carried out in the +4 oxidation state. Chemical speciation depends, 
amongst other factors, on the composition of the system, pH, temperature, ionic strength and 
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time.
9
 The pH-metric speciation was done on the biological pH range of 2 to 7.4. The species 
distribution diagrams were generated using the program HySS.
10
 In this study the speciation 
modeling was done through the stability constants approach. The stability constants of 
oxovanadium(IV)-amino acid derivatives in aqueous solution were studied potentiometrically 
and results were computed using the program HYPERQUAD. The glass electrode was 
calibrated for a strong acid-base reaction by the Gran method
11
 using the software GLEE to 
obtain Eº.
12
 The data obtained from these titrations were used to calculate the protonation and 
stability constants. 
2.3.1 Potentiometry and HYPERQUAD 
The concentration stability constants (βpqr) were calculated using the computer program 
HYPERQUAD
13
 (extension of SUPERQUAD). This program makes use of the following 
assumptions to calculate the formation constants: 
(i)  For each chemical species MpLqHr in the solution equilibra there is a chemical constant 
which is expressed as: ; where M, L and H represent a metal, ligand and 
proton respectively. 
(ii)  The electrodes used, have a pseudo-Nernstian behaviour. 
(iii) Careful calibration of the electrode, accurate standardization of reagents, elimination of 
weighing and dilution errors, elimination of carbonate impurities, elimination of temperature 
variance and purity of water minimise the systematic errors. All statistical tests are based on 
the assumption that systematic errors are absent. 
(iv) The program assumes that the independent variables (such as titre volume) are not 
subject to errors and that the dependent variables (such as measured potential) have a normal 
distribution. If this is the case then the calculated residuals should not show systematic trends. 
(v) For any equilibrium system, a model exists that will fit the experimental data. All least-
square refinements are performed in terms of the assumed model. The model that is found 
may not be the true model, but it will be the one that fits the observed data. It will have no ill-
defined constant and the standard deviation. A constant is considered ill-defined if its 
standard deviation is more than 33% (such standard deviations are labelled "Excessive") or if 
its value is negative. 
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The program calculates the stability constants using a non-linear least-square refinement 
algorithm based on following the acid concentration in complex acid-base equilibra using the 
proton sensitive glass electrode. The concentration of the hydrogen ion in solution is related 
to the potential measured with the electrode by the modified Nernst equation, E = E
o 
+ RT/F 
ln . The standard potential, E
o
, must be determined for the specific conditions of 
operation via the calibration of an electrode for a strong acid-base titration using the Gran 
method.
11
 
The concentrations of the chemical species are determined by solving the non-linear 
simultaneous equations of mass-balance using the Newton-Raphson method. The program 
allows for up to four reactants and up to 18 species. The equilibra for the specific interactions 
of the reagents, M (metal) and L (ligand), with H (proton) are M + iH  =  HiM; L +  jH  =  
HjL; and the total concentrations (TM, TL, TH) of the species is given by: 
TM   =   [M]    +     
TL    =   [L]    +     
TH   = [H] + +  
Mass-balance equations must be satisfied and hence the total concentrations of a reagent is 
the sum of its concentrations in all the chemical species in the mixture. Once the free reactant 
concentrations ([M], [L], [H]) have been calculated, the concentrations of the complexes are 
derived from them and the equilibrium constants (during model fitting, the constants must be 
estimated). The best fit to the experimental data is determined by minimizing the error square 
sum of the residuals, U =  ,  where wi is the weighting factor. The model 
can be proposed for the equilibrium system, which adequately accounts for the experimental 
observations. The model is specified by a set of coefficients (p,q,r), one for each species in 
terms of the assumed model. Choice of the “best” model is based on two statistical values, 
sigma ( ) and chi
2
 (χ2). Ideally  should be equal to one but it has been proposed that any fit 
with  < 3 is satisfactory. χ2 is also useful for model selection, with χ2 < 12.6 corresponding 
to a 95% confidence level. If  and χ2 are large, then the experimental data points with larger 
residuals must be removed during the refinement if the specified model is a promising fit.  
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2.3.2 HPLC speciation studies 
The recognition of the fact that the chemical, biological, toxicological properties of an 
element are critically dependent on the form in which the element occurs in the sample has 
spurred a rapid development of an area of analytical chemistry referred to as speciation 
analysis.
8
 A fundamental tool used for the speciation studies is the chromatographic 
separation techniques, that ensure that the species leave the column unaccompanied by other 
species of the analyte element.
14
 Particular attention is given to the limitations related to the 
chromatographic signals identification due to unavailability of standards for many species 
since a large number of compounds have not yet been identified and characterized.
14-16
 
Recently, several reports on the determination of trace amounts of heavy metals by high 
performance liquid chromatography (HPLC) have appeared.
17-20
  For example, Hidekazu 
Yamada et al
21
 determined trace amounts of vanadium in plant materials by reverse–phase 
liquid chromatography.  
This technique was used to identify and separate oxovadium(IV)-amino acid species.  This 
study was carried out to complement the pH-metric speciation modeling study done on the 
VO-amino acid system by potentiometry and HYPERQUAD. Our model fitting results 
contradicted with those obtained by other researchers but this will be discussed in detail in 
chapter 3. The method and operating conditions are shown in table 2.2.  
Table 2.2: HPLC isocratic method and operating parameters. 
Parameter Setting 
Mobile phase 0.01 M phosphate buffer, pH 7.4 
Wavelength 250 nm 
Detector DAD 
Column Gemini C18,  100mm x 4.6 mm x 5 µm 
Column temperature ambient 
Flow rate 0.5 ml/min 
Sample injection volume 20 µL 
Run time 15 minutes 
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2.4 Biological studies 
The in vitro testing for the biological anti-diabetic activity of the synthesized 
oxovanadium(IV) complexes was done. Three primary cell culture lines C2C12 (muscle), 
3T3-L1 (fat) and Chang liver cells were used to investigate the potential of the synthesized 
oxovanadium(IV) complexes on glucose uptake. Cell viability tests were done before the 
glucose uptake studies to establish non-toxic concentrations of the compounds. 
2.4.1 Maintenance of cells lines 
3T3-L1 preadipocytes, were maintained in Dulbecco’s modified eagle medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), while C2C12 mouse skeletal myoblasts 
and Chang liver cells were maintained in RPMI-1640 medium (Sigma) supplemented with 
10% FBS. These were incubated at 37 
o
C in a humidified incubator with 5% CO2. Cells were 
subcultured at 70% confluence and seeded at a density of 35 000 cells/ml (for 3T3-L1) and 
25 000 cells/ml (for Chang and C2C12) in 24-well culture plates. 
2.4.2 MTT Assay 
Methods for cell viability determination in vitro are required for many different biological 
assays. The MTT-cell proliferation assay is a quantitative colorimetric assay for 
measurements of cellular proliferation, viability, and cytotoxity.
22-24
 The assay is based on 
cleavage of the yellow tetrazolium salt, MTT, which forms water-insoluble, dark blue 
formazan crystals. This cleavage only takes place in living cells by the mitochondrial enzyme 
succinate-dehydrogenase.
24
 The water-insoluble formazan can be solubilised using 
isopropanol or another organic solvent. The optical density of the dissolved material is 
measured spectrophotometrically, yielding absorbance as a function of concentration of 
converted dye, which directly correlates to the number of metabolically active cells in the 
culture.
22,26,27
 
Cells were seeded in 24-well plates (Nunc) at densities of 25 000 for C2C12 and Chang liver 
cells, and 35 000 cells/mL for 3T3-L1. After overnight attachment, the culture medium was 
replaced with medium containing the test compounds at a range of concentrations (0.01–10 
µM). Cells were incubated for 48 h at 37 
o
C, after which the MTT assay was performed.
22
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2.4.3 Glucose assay 
The glucose uptake studies was performed using the GLUCOSE (Glu-cinet) kit (BAUER)
28 
 
which contains glucose oxidase and peroxidase. Glucose oxidase catalyses the conversion of 
glucose to gluconic acid and hydrogen peroxide. The hydrogen peroxide reacts with a 
reduced dye, 4-aminoantipyrine, to produce oxidized dye and water. The reduced form of the 
dye is colourless while the oxidized form is reddish in colour. The coloured compound is then 
measured spectrophotometrically at a wavelength of 492 nm (A492).
28
 
Control cells were represented by untreated differentiated fat (3T3-L1), liver (Chang) and 
muscle (C2C12) cells incubated in culture media. Positive control cells (Met) were 
represented by untreated differentiated fat, liver and muscle cells exposed to metformin. Cells 
were then exposed for 48 h to the test compounds. Thereafter glucose uptake was determined 
and the cell number was normalized using the MTT assay, as laid out by Mossman.
22
 
2.4.4 Statistical analysis 
Error bars indicate the standard error of the mean (SEM) unless specified otherwise (n = 3). 
The two-tail paired test was used to determine significance of results (p < 0.05) and (p < 
0.01). 
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CHAPTER 3 
AMINO ACID COMPLEXES OF OXOVANADIUM(IV) 
 
3.1 Introduction 
The equilibria in aqueous solutions of vanadium have been studied thoroughly by different 
experimental methods.
1 
The data in the literature, however, are rather contradictory. The soft 
character of the VO
2+
 ion was stated by Ramakrishna et al
2
 by comparing the stability 
constants of the complexes formed with thiosalycilic and salycilic acids, although Chatt and 
Ahrland
3
 as well as Pearson
4 
classfied the vanadyl ion as a typical hard acid. Reeder and 
Rieger
5 
interpreted the stability of the VO
2+
 α-OH-carboxylic and α-SH-carboxylic acids as 
due to the formation of coordinative δ and π bonds. They concluded that the VO2+ ion cannot 
form stable complexes with ligands containing no electron pair for π-bonding (e.g. amines), 
yet several authors have reported the formation of stable complexes with ligands containing 
an amine donor group.
6-7
 Solution studies have been carried out on the interaction of VO
2+
 
with amino acids; ʟ-alanine, glycine, ʟ-serine, ʟ-threonine, ʟ-cysteine, ᴅ-penicillamine, ʟ-
aspartic acid, ʟ-glutamic acid and ʟ-histidine using potentiometric, spectroscopic and NMR 
relaxation techniques.
8-11
 The results show different solution chemistry models but there is 
evidence of bidentate coordination in the complexation. 
In pH-potentiometric investigations of solutions containing VO
2+
 and N-donor ligands, a 
relatively high pH is necessary to achieve an appropriate free ligand concentration for 
complex formation.
8
 At pH>4, however, hydrolysis of VO
2+
 ion takes place and oxidation to 
V(V) may also be significant unless deoxygenation is carried.
9
 Another difficulty is that the 
nature (and formation constants) of the hydrolysis products of VO
2+
 in the pH range 5-12 is 
not very well understood.
8
 Studies done on glycine-VO
2+
 system in the pH range 2-7 mainly 
by spectrophotometric measurements used models that included hydrolysis species, 
[VO(OH)]
+
 and [(VO)2(OH)2]
2+
.
9
 The equilibria in aqueous solution in the VO
2+
-amino acid 
systems show results with models that include species; MLH, ML, ML(OH)2, ML2H2, ML2H, 
ML2, ML2OH, M2L2(OH)2 and M2L2(OH)3 (where M denotes vanadyl ion and L denotes a 
deprotonated amino acid ligand).
9
 A potentiometric and spectroscopic study of the 
complexation of oxovanadium(IV) by the sulphur-containing amino acids ʟ-cysteine and ᴅ-
penicillamine differ from those for the ʟ-alanine, ʟ-Serine, ʟ-threonine, ʟ-aspartic acid and ʟ-
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glutamic acid systems for much of the pH range studied (1.8-13.5).
10 
This difference stems 
from coordination of the thiol group at quite low pH (~ 4). The nature of species present in 
neutral or basic solutions is still controversial but it is clear that for pH>5 other hydrolysis 
products predominate which should be included in any equilibrium model, especially for 
systems like ʟ-alanine-VO2+ and glycine-VO2+ where, even using high ligand-to- metal ratios 
for pH>7-8, solutions have a brown colour, in contrast to serine-VO
2+,
 cysteine-VO
2+ 
and 
aspartic acid-VO
2+
 systems. One main problem in calculations with HYPERQUAD
26
 for the 
glycine-VO
2+
 and ʟ-alanine-VO2+ systems is the importance of hydrolysis products of VO2+ 
in the pH range 5-8.
11
 The nature of such products and their formation constants are not 
accurately known and this is the main reason why there are so many models suggested for the 
same system. 
Amino acid derivatives have provided encouraging in vitro and in vivo results from anti-
diabetic studies with vanadium(V) and (IV) glutamic-γ-hydroxamic acid complexes12 and 
vanadyl-cysteine methyl ester which showed activity equivalent to that of vanadyl sulfate
13
. 
A lot of work has been done on the interaction of oligopeptides with the vanadyl ion. For 
example, dipeptides such as glycyl-tyrosine coordinate to vanadate via the terminal amino 
and carboxylate functions plus the deprotonated amide takes place along with reduction of 
vanadate to vanadyl
14
. Direct coordination of the deprotonated OH functional group in amino 
acids such as ʟ-tyrosine, ʟ-serine, ʟ-threonine and О-vanillin has not been observed in 
vanadium(IV) complexes. Although the isolation of solid complexes of the VO
2+
 cation and 
simple amino acids has often been claimed
15
, pure compounds have apparently never been 
isolated from any aqueous oxovanadium(IV)-amino acid system until recently. The first 
isolated oxovanadium(IV) complex, [VO(His)4]SO4.2H2O,
17
 showed that the interaction of 
VO
2+
 and ʟ-histidine forms a 1:4 species although solution speciation modeling studies 
suggest that a 1:2 complex is dominant at pH 7.
18
 However, an oxovanadium(IV) histidine 
complex, [V
IV
O(hist)2]ClO4.H2O, has also been isolated and the structure determined by X-
ray crystallography.
 19
 It adopts a distorted octahedral structure with one ʟ-histidine ligand 
coordinated to the oxovanadium(IV) center in a tridentate fashion as a monoanion and the 
other in a bidentate fashion leaving a protonated imidazole group as a pendent group. 
Since the ligand must dissociate from the vanadyl ion for the compound to be 
pharmaceutically active, use of well studied, non-toxic ligands becomes a priority. In this 
work we have chosen glycine and ʟ-alanine as the amino acids which are bioligands. Glycine 
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is one of the non-essential amino acids and is used to help create muscle tissue and convert 
glucose into energy, hence its synergetic effects as a possible non-toxic anti-diabetic organo-
vanadium pharmaceuticals is worth pursuing. We have, however, not been able to isolate a 
pure compound with glycine but we are certain of the purity of the alanine derivative that we 
have isolated.  
 
3.2 Experimental 
3.2.1 Reagents 
Vanadyl sulfate trihydrate was obtained from BDH Limited (England). ʟ-alanine (97%) (1a), 
glycine (98%) (1b), tetramethylammonium hydroxide (TMAOH) (10w%) and 
tetramethylammonium chloride (TMACl) (97%) were obtained from Sigma-Aldrich (USA).  
Hydrochloric acid (1 M) (analytical grade) and all solvents (reagent grade) were obtained 
from Merck Chemicals (SA) and used without further purification. Other reagent grade 
chemicals were also obtained from commercial sources and used as received. 
3.2.2 Preparative work 
(a) Synthesis of [VO(ala)4(H2O)]SO4.3H2O (2a) 
ʟ-alanine (1.32 g, 14.9 mmol) and vanadyl sulfate trihydrate (0.32 g, 1.4 mmol) were refluxed 
for 3 hours in ethanol and a light blue precipitate started to form. The light blue mixture was 
left to cool to room temperature overnight. The light blue solid was filtered off, washed with 
cold water and ethanol and finally dried in an oven at 100 
o
C. Yield: 93.2%. Mp = 272-276 
o
C. IR ν (neat): 3352(m), 3119(m), 2937(m), 2825(m), 2739(m), 2617(m), 2532(m), 1745(s), 
1698(vs), 1510(s), 1456(s), 1398(m), 1345(m), 1294(m), 1247(m), 1208(m), 1105(s), 
1026(s), 956(vs), 857(s), 839(m), 532(s), 402(m) cm
-1
. Anal. Calc (found). for 
C12H36N4O17SV (591.44); C, 24.37 (24.15); H, 6.14 (6.21); N, 9.47 (8.06); S, 5.42 (6.23)%. 
UV/Vis (solid reflectance), λmax  (nm): 356, 587, 647, 810. 
(b) Synthesis of [VO(gly)4(CH3CH2OH)]SO4 (2b) 
This complex was prepared similarly to 2a. Glycine (1.21 g, 16.1 mmol) and vanadyl sulfate 
trihdrate (0.35 g, 1.61 mmol) were refluxed for 3 hours in ethanol and a light blue precipitate 
started to form. The light blue mixture was left to cool to room temperature overnight. The 
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blue solid was filtered off, washed with cold water and methanol and finally dried in an oven  
at 100 
o
C. Yield: 89.3%. Mp = 198-200 ºC. IR ν (neat): 3149(m), 3007(m), 2967(m), 
2820(m), 2516(m), 1749(s), 1577(vs), 1494(s), 1441(s), 1405(s), 1330(s), 1191(m), 1107(s), 
1031(s), 973(vs), 905(s), 890(s), 536(s), 464(m) cm
-1
. Anal. Calc (found). for C11H28N4O14SV 
(523.36); C, 25.24 (25.52); H, 5.39 (5.74); N, 10.71 (14.72); S, 6.13 (2.50)%. UV/Vis (solid 
reflectance), λmax (nm): 344, 502, 612, 797. 
3.2.3 ICP-OES analysis 
Compounds 2a (4.850 mg) and 2b (5.291 mg) were separately dissolved in water and 
acidified with traceselect nitric acid and made up to 25 ml in a volumetric flask. Standard 
solutions containing 1 ppm, 2 ppm, 5 ppm, 10 ppm and 15 ppm of vanadium, were used to 
construct a calibration curve. Three wavelengths were used (290.8, 292.4 and 311.0 nm) for 
the detection of vanadium to ensure accuracy, and three repeats were performed at each 
wavelength. The best wavelength from the calibration curves was 292.4 nm. The vanadium 
content of compounds 2a and 2b at the most sensitive line, 292 nm, was 17.04(8) ppm and 
22.60(9) ppm respectively.  Vanadium content as a percentage for compound 2a was found 
(calculated); 8.78 (8.61)% and for 2b; found (calculated): 9.54 (10.0)%. 
3.2.4 Potentiometric studies 
The protonation and stability constants for the ligands and oxovanadium(IV) complexes were 
determined by potentiometric titration of approximately 25 ml samples. All solutions were 
prepared using freshly boiled and degassed deionized milli-Q water to ensure the removal of 
dissolved oxygen and carbon dioxide. The ligand concentration was 1 mM and metal-to-
ligand ratios of 1:1, 1:2 and 1:10 were used. Titrations were performed over the pH range of 
2-11 under a continuous flow of purified nitrogen using HCl and tetramethylammonium 
hydroxide (TMAOH). The vanadium stock solution containing 0.10 M HCl was standardized 
by titration with permanganate. The ionic strength of the titration solutions was kept constant 
at 0.10 M tetramethylammonium chloride (TMACl). The use of the bulky, non-coordinating 
cation, tetramethylammonium, was to eliminate the use of the non-innocent potassium and 
sodium ions in KCl and NaCl with respect to coordination in order to ensure that the model is 
fitted on accurately collected data. Titrations were controlled using the Tiamo software. The 
titration rate used was 0.01 ml/min and the pausing time was 60 s. The glass electrode was 
calibrated for a strong acid-base reaction by the Gran-method
20
 using the program GLEE
21
, to 
determine the standard potential, E
o
. The ionic product of water (pKw) of 13.83(1) at 25.0±0.1
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o
C in 0.10 M TMACl was used in all calculations
22
. The following hydrolysis model of a 
vanadyl system was included in the model; [(VO)2(OH)5]
-
 (logβ20-5 = -22.0)
23
 and  
[VO(OH)3]
-
 (logβ10-3 = -18.0), while [(VO)2(OH)2]
2+
 (logβ20-2 = -6.95) and [VO(OH)]
+
   
(logβ10-1 = -5.94)  did not fit. The concentration stability constants βpqr = 
[MpLqHr]/[M]
p
[L]
q
[H]
r
 were calculated by using the computer program HYPERQUAD
24
. The 
final values of the constants were obtained from an average of eight independent titrations 
using an average of around 400 data points in total for each refinement.  
3.2.5 HPLC separations 
A mixture of vanadyl sulfate trihydrate (213 mg) and glycine (147 mg) was dissolved in 25 
ml of 0.001 M phosphate buffer pH 7.4. Another mixture of vanadyl sulfate trihydrate (205 
mg) and ʟ-alanine (168 mg) was dissolved in 25 ml of 0.01 M phosphate buffer pH 7.4. The 
mobile phase, 0.01 M phosphate buffer pH 7.4 was prepared by mixing KH2PO4 (1.370) and 
NaHPO4 (1.099 g) and dissolved it in 1 L water. The mobile phase solution was filtered 
through a 0.45 µm membrane filter and degassed before use. The sample solutions were 
prepared immediately before analysis, and 20 µL were injected on to the column. The mobile 
phase flow rate was 0.5 ml/min and the eluted vanadium(IV)-amino acids species were 
detected at 254 nm. 
 
3.3 Results and discussion 
3.3.1 Synthesis of complexes 
The synthetic goal of this work was to prepare neutral vanadium complexes containing 
bidentately coordinated low molecular mass amino acids, glycine and ʟ-alanine (see scheme 
3.1). Initial attempts to prepare the bis(amino acid) oxovanadium(IV) complexes employed a 
literature method with slight modifications.
25
 To a stirred aqueous solution of amino acid, an 
equimolar amount from 10% tetramethylammonium hydroxide (TMAOH) solution was 
added. To this solution was added aqueous VOCl2 (half mole equivalence to the amino acid 
ligand, prepared by the reaction of VOSO4 with BaCl2). The reaction yielded dark green 
precipitates of a mixture of the oxovanadium complex species with hydrolysis products as 
dominant species. In another attempt to synthesize 1c and 1d, vanadyl sulphate was stirred 
with the ʟ-alanine or glycine in phosphate buffer of pH 7.4 and pH 7.9 respectively under 
inert conditions. However, vanadium hydrolysis products and vanadyl-phosphate precipitates 
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were observed (see figure 3.1). Elemental analysis revealed that there were no amino acids in 
the isolated precipitates from these phosphate buffered reactions. Stirring vanadyl sulfate 
alone in the phosphate-buffered solutions yielded the same precipitates and this confirmed 
that precipitates of vanadium phosphates were formed. 
Wavenumber (cm
-1
)
1000200030004000
%
T
ra
n
sm
it
an
ce
50
60
70
80
90
100
VO(ala)
x
(OH)
y
VO(ala)
x
(PO
4
)
y
 
 
Figure 3.1: IR spectra of vanadium hydrolysis (VO(ala)x(OH)y) and vanadyl-phosphates 
(VO(ala)x(PO4)y). x and y are hypothetical stoichiometric coefficients. 
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Scheme 3.1: Attempted synthesis of [VO(gly)2] (1c) and [VO(ala)2] (1d) 
In an effort to circumvent hydrolysis, another synthetic route was adopted where the amino 
acid and vanadyl sulfate trihydrate were refluxed in ethanol. The elemental analysis data and 
spectral characterization suggested the chemical formulae, [VO(ala)4(H2O)]SO4.3H2O (2a) 
and [VO(gly)4(CH3CH2OH)]SO4 (2b) (where ala is ʟ-alanine and gly is glycine). 
[VO(ala)4(H2O)]SO4.3H2O was very hygroscopic and readily dissolves in water. In 2b, it is 
not certain if the ethanol is coordinating to the metal or it is ethanol of crystallization and 
these complexes need to be further characterized by single crystal X-ray diffraction. It was 
impossible, however, to recrystallize the two complexes because both of them underwent 
decomposition in most of the usual solvents. The composition of the complexes was further 
supported by the ICP-OES analysis results (see under section 3.2.3). The vanadium content 
was the same as the vanadium content from the suggested empirical formula in both 
complexes, [VO(ala)4(H2O)]SO4.3H2O and [VO(gly)4(CH3CH2OH)]SO4. Thermal analysis 
techniques, such as DSC, TGA, and especially TG-FTIR analysis, could be employed for 
further characterization of these complexes. 
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Figure 3.2: Proposed structures of [VO(ala)4(H2O)]SO4.3H2O (2a) and 
[VO(gly)4(CH3CH2OH)].SO4 ( 2b) 
3.3.2 Spectroscopic characterization 
A comparison of the most relevant IR bands of the amino acid ligands (glycine and ʟ-alanine) 
and their corresponding oxovanadium complexes is shown in table 3.1.  The assignments of 
the ʋ(V=O), ʋ(N-H), ʋ(C-H), ʋ(C=O), ʋas(COO
-
), ʋs(COO
-
), ʋ(V-N), δ(O-H), δ(COO-), 
δ(NH2), δ(NH3
+
) vibrations were made according to literature.
17,26
 The presence of the 
ʋas(COO
-
), δ(NH3
+
), ʋs(COO
-
) and the absence of ʋ(C=O) bands around 1750 cm-1 in both 
glycine and ʟ-alanine confirm that the amino acids exist as zwitterions. Complexes, 2a and 
2b, exhibit the characteristic peak for VO
2+
 stretch vibration at 973 cm
-1
 and 953 cm
-1
 
respectively (see figure 3.3). The V-N bands appear at 532 cm
-1
 and 536 cm
-1
 for complexes 
2a and 2b respectively and are within reported ranges.
27,28
  
In the comparison of the vibrations in the free amino acids ligands and complexes, there are 
major shifts associated to the δ(NH2), ʋ(N-H), δ(NH3
+
), suggesting a coordination involving 
the amino group. There is not much change in the carboxylate stretches suggesting that 
carboxylate is not involved in the coordination. The position and non-splitting of the 
antisymmetric stretching vibration (around 1100 cm
-1
) of the sulfate ion indicate that this 
anion is not coordinated to the metal centre.
29
 The ʋ(V-O) bands in the complexes can be 
attributed to the water and ethanol molecules coordinating to the VO
2+
 (see figure 3.4). The 
proposed coordination in figure 3.2 was also seen in the first isolated oxovanadium of ʟ-
histidine.
17
 The water molecules are responsible for the O-H stretch in the region 3400 cm
-1–
3000 cm
-1
.  
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Figure 3.3: Mid-IR spectra of [VO(ala)4(H2O)]SO4.3H2O and [VO(gly)4(CH3CH2OH)]SO4 
   Wavenumber (cm
-1
)
100 200 300 400 500 600 700
%
 T
ra
n
sm
it
an
ce
0
10
20
30
40 L-alanine 
[VO(ala)
4
(H
2
O)]SO
4
.3H
2
O
 
953  cm-1 
973 cm-1 
ʋ(V-O) 
ʋ(V-N) 
46 
 
Figure 3.4: Far-infrared spectra of [VO(ala)4(H2O)]SO4.3H2O 
Table 3.1: Characteristic IR bands of amino acid ligands and their corresponding 
vanadium(IV)  complexes.  
ʟ-Alanine (cm-1) Glycine (cm-1)  2a (cm-1)  2b (cm-1) Assignment 
3068(m) 3149(m) 3352(m) 3149(m) ʋ(O-H) 
3002(m) 3007(m) 3119(m) 3007(m) ʋ(N-H) 
2982(m)    
2981(m)  
2967(m), 2891(m) 
2937(m)  
2739(m) 
2967(m), 
2602(m) 
ʋ(C-H) 
- - 1745(s) 1749(s) ʋ(C=O) 
1580(vs) 1577(vs) 1598(vs) 1577(vs) ʋas(COO
-
) 
1527(s) 1497(s) - - δ(NH3
+
) 
1451(s) 1441(s) 1456(s) 1441(s) ʋs(COO
-
) 
1406(s) 1406(s) 1398(m) 1405(s) δ(C-H) 
1350(s) 1327(s) 1345(m) 1330(s)  δ(O-H) 
1236(s) 1257(m) 1247(m) 1191(m)  ʋ(C-N) 
- - 1105(s), 1026(m) 1107(s), 1031(s) ʋ(SO4
2-
) 
- - 973(vs) 953(vs) ʋ(V=O) 
 890(s) 849(m) 857(s) 905(s) δ(NH2) 
766(s) 693(s) - - δ(COO-) 
- - 532(s) 536(s) ʋ(V-N) 
- - 402(m) 464(m) ʋ(V-O) 
(s = strong, vs = very strong, m = medium, ʋas = asymmetrical stretching mode, ʋs 
symmetrical stretching mode and δ = bending mode). 
 
Theoretically, for a C4v complex, three transitions should be observed in the region 1000 – 
330 nm, corresponding to three d-d transitions (as discussed in chapter 2). Four bands may be 
observed when lowering the symmetry to C2v since the degeneracy of the eπ level may be 
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removed.
26
 The UV-vis solid reflectance spectra of the complexes 
[VO(gly)4(CH3CH2OH)]SO4 and [VO(ala)4(H2O)]SO4.3H2O are shown in figures 3.5 and 
3.6.  The UV-vis solid reflectance spectrum of [VO(gly)4(CH3CH2OH)]SO4 exhibits peaks at 
795, 612, 502 and 344 nm, which can be assigned to the (dxy → dxz,), (dxy → dyz), (dxy → dx2 – 
y
2) and (dxy → dz2) transitions respectively.  The UV-vis spectrum of 
[VO(ala)4(H2O)]SO4.3H2O exhibits similar transitions at 810, 647, 587 and 356 nm. The four 
ligands are probably arranged equatorially around the VO
2+ 
cation, generating a square-
pyramidal complex. However, one of the four water molecules in 2a and ethanol molecule in 
2b, may also be involved in coordination, occupying the position trans to the V=O bond. 
This arrangement is often found in oxovanadium(IV) complexes
30
, generating a distorted 
octahedral complex. The four bands found in [VO(ala)4(H2O)]SO4.3H2O and 
[VO(gly)4(CH3CH2OH)]SO4 are as a result of a large splitting of dxz and dyz orbitals. The 
relative movement of the z
2
 level is far less predictable, since it is primarily involved in 
sigma bonding to the axial oxygen and only secondarily involved in the equatorial sigma 
bonding, e.g., as a hybrid (4s-dz
2
).
31
 
 
Wavenumber (nm)
400 500 600 700 800
A
bs
or
ba
nc
e
0.06
0.08
0.10
0.12
0.14
0.16
0.18
0.20
0.22
[VO(gly)4(CH3CH2OH)]SO4
344 nm
502 nm
612 nm
797 nm
 
Figure 3.5: UV-vis solid reflectance spectra of [VO(gly)4(CH3CH2OH)]SO4   
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Figure 3.6: UV-vis solid reflectance spectra of [VO(ala)4(H2O)]SO4.3H2O  
 
3.3.3 pH-metric solution speciation studies 
The protonation constants of the ligands were calculated from an average of four independent 
titrations while an average of eight titrations were used for the stability constants calculations. 
The fitted curve (the one calculated by the HYPERQUAD program) tallied well with the 
titration curve for the proposed model (figure 3.7). The experimental data points with larger 
residuals were removed during the refinement. Data from the regions in which there was no 
complex formation and in a region in which complex formation was essentially complete 
were excluded (the red points in figure 3.7) from the calculations since they contributed no 
information regarding the formation constants. The statistical error (σ) was below 3 for all the 
refinements. The protonation (logK) and oxovanadium complex formation (logβ) constants 
are listed in Table 3.2 together with standard deviations.  
 
 
49 
 
Obs-calc pH for selected data. sigma=0.1863
20 40 60 80 100
point number
-0.5
0
0.5
0
10
20
30
40
50
60
70
80
90
100
%
 f
o
rm
a
ti
o
n
 r
e
la
ti
v
e
 t
o
 M
VO-glycine system
3
5
7
9
11
p
H
 
 
Obs-calc pH for selected data. sigma=0.6440
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Figure 3.7: Titration and fitted curves of VO-glycine (A) and VO-alanine (B) systems. 
Experimental points (blue squares) and calculated (red continuous line). The other lines 
represent the species (not specified) 
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 The ligands exhibit two protonation processes in the pH range 2-11 for the carboxylate and 
amine groups respectively. The logK1 and logK2 values depict the dissociation of the 
carboxylate and amine groups respectively. The protonation constants of glycine, 
pK1=2.58(1) and pK2=9.32(1), are in agreement with previous reports.
8,32
 The difficulty in the 
pH-metric investigation of the VO
2+
-N-donor ligands is that the deprotonation of the N-
donors in general takes place in alkaline medium as shown in figures 3.7 and 3.8, and the 
amine group of both glycine and ʟ-alanine is free from pH 8, hence relatively high pH is 
necessary to achieve an appropriate free ligand concentration for complex formation. This 
necessitated for large amounts of ligand (1:10 M:L) in order to prevent precipitation of the 
hydrolysis species. 
 
Table 3.2: Protonation (logK) and stability (logβ) constants for the VIVO-Glycine and VIVO-
ʟ-alanine systems at I = 0.10 M TMACl and T = 25.0±0.1 oC. Standard deviations (errors in 
the last digit) are reported in parenthesis. 
 
                            Reaction 
            Ligand 
Glycine ʟ-alanine 
pK1 LH2
+
  H
+
 + LH 2.58(1) 2.20(1) 
pK2 LH  H
+
 + L
-
 9.32(1) 9.62(1) 
logβ110 VO
2+
 + L
-
   [VO(L)]
+
 11.27(6) 9.89(5) 
logβ111 VO
2+
 + H
+
 + L
-
   [VO(LH)]
2+
      - 11.16(3) 
logβ120 VO
2+
 + 2L
-
  [VO(L)2] 17.22(6) 18.27(6) 
LH2
+
 = protonated ʟ-alanine or glycine, LH= ʟ-alanine or glycine 
And L
-
= deprotonated ʟ-alanine or glycine. 
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Scheme 3.2:  The stepwise formation of oxovanadium(IV) complexes. ʟ-alanine (LH) and 
and deprotonated ʟ-alanine ( L-) are omitted in the complexation equilibria. The hydrolysis 
equilibria and the charges are also omitted. 
 
 
  
Figure 3.8: Species distribution as a function of pH for glycine. Gly
-
=deprotonated glycine, 
GlyH=glycine and GlyH2
+
=protonated glycine 
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Figure 3.9: Species distribution as a function of pH for ʟ-alanine. Ala-= deprotonated ʟ-
alanine, AlaH= ʟ-alanine, AlaH2
+
=protonated ʟ-alanine 
 
 
Figure 3.10: Speciation curves for complexes formed in the (V
IV
O)-glycine system 
(VO
2+
:GlyH is 1:4) 
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Figure 3.11: Speciation curves for complexes formed in the (V
IV
O)-ʟ-alanine (B) system 
(VO
2+
:AlaH is 1:4)  
 
Both the (V
IV
O)-glycine and V
IV
O-ʟ-alanine systems revealed the presence of the species of 
interest, [VO(gly)2] and [VO(Ala)2], which  formed at pH 3.5-11 and pH 1.5-12 respectively 
(see figures 3.10 and 3.11). Both systems cover the biological pH. At pH>3, however, the 
hydrolysis of the vanadyl ion takes place and this necessitated the use of 10:1 (glycine:VO
2+
) 
molar ratio in order to suppress metal ion hydrolysis and possible concomitant precipitation 
of vanadium(IV) hydroxide species.
32
  
HPLC speciation was done to confirm the presence of these species at pH 7.4 using a 
phosphate buffer system. To control the pH of the system, the phosphate buffer was used to 
prepare samples and the mobile phase.  The elution of free uncoordinated vanadyl using the 
phosphate buffer as the mobile phase gave a signal at a retention time of 3.4 min. Two 
prominent peaks were observed in both systems at pH 7.4 and they suggest [VO(Gly)2] 
(retention time = 3.1 min) and VO
2+
-phosphate (retention time = 3.4 min) in VO
2+
-glycine 
system and VO
2+
-phosphate (retention time = 3.4 min) and [VO(Ala)2] (retention time = 4.1 
min) in VO-ʟ-alanine system (see figures 3.12 and 3.13). The third smallest peak in 
VO
2+
/glycine system is assigned to [VO(Gly)]
+
 (retention time = 6.3 min).  This agrees well 
with the species identified by potentiometric methods (see figures 3.10 and 3.11. However, 
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optimised separations of the fractions and further characterisation by LC-MS are needed to 
confirm these observed species. We can say that our pH-potentiometric solution model is 
reasonably well fitted despite the contradictions with literature
9
 where several other species 
were identified in addition to our observations. But this will be qualified by a greater 
coverage of the pH ranges with these HPLC separations and confirmation by LC-MS. 
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Figure 3.12: An HPLC chromatogram of VO
2+
/glycine mixture at pH 7.4 
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Figure 3.13: An HPLC chromatogram of VO
2+
/ʟ-alanine mixture at pH 7.4 
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The fitting of the titration data supports the formation of monomeric [VOL]
+
 and [VOL2] 
species for both ligands as well as [VOLH]
2+
 for L-alanine. The hydroxo binding 
([VOL2(OH)]
-
 could not be fitted in both models while the assumption of the binary hydroxyl 
species [(VO)2(OH)5]
-
 as well as [VO(OH)3]
-
 in highly basic solutions fitted well. It is 
possible, however, to confirm these hydrolysis species by EPR spectroscopy since they are 
both EPR-active. The overall stability constant for the (V
IV
O)-L-alanine system (log β120 = 
18.27(6)) is larger than for the glycine system (β120 = 17.22(6)). This can be explained by the 
fact that the amine nitrogen in ʟ-alanine is more basic than that of glycine. The overall 
stability constants of both the V
IV
O-glycine and V
IV
O-ʟ-alanine system are comparable to 
those given in literature
32 
although the models and methods are different. For V
IV
O-ʟ-alanine 
system, however, the coordination of a protonated ligand is observed at low pH with logβ111 
= 11.16(3). This suggests strong binding and the possibility of a symmetrically chelating 
carboxylate ion, with the amine nitrogen protonated. For the formation of monomeric [VOL]+ 
and [VOL2] species (L=ligand), the very acidic carboxylic acid groups interact with VO
2+
 at 
very low pH and the mildly basic amine nitrogen able to interact with vanadyl at relatively 
higher pH. The result is the stabilization of these oxovanadium(IV) complex systems in the 
relavant biological pH. Although recent studies on VO
2+
-amino acid systems show that at pH 
6-8, the predominant species in solution is a 1:2 complex, solid state studies suggest that a 1:4 
species can also be formed, such as the case with our isolated compounds. 
3.3.4 Biological studies 
The use of in vitro studies to evaluate the glucose uptake in cell lines following stimulation 
with insulin and other active compounds is a direct and sensitive method of determining the 
antidiatogenic effect of these compounds.
33,34
 It allows for rapid screening of compounds in 
terms of their efficacy and toxicity in an ethically acceptable manner. Although the in vitro 
environment does not accurately mimic the in vivo situation, it offers unique opportunities 
and insights into the biochemical pathways which control the utilization of glucose by 
different cell types following exposure to various agents with potential diabetogenic effects.
34
 
Cytotoxicity and glucose uptake by vanadyl sulfate (VOSO4) and oxovanadium(IV) complex 
of ʟ-alanine (2a) on 3T3-L1 adipocytes, Chang liver and C2C12 muscle cells was done. The 
purity of oxovanadium(IV) complex of glycine as well as its characterization was not 
satisfactory and hence it was not included in the biological studies. 
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(a) Cytotoxicity 
 The results of the cytotoxicity of vanadyl salt and vanadium complex are presented in figure 
3.13. The vanadium compounds (VOSO4 and [VO(ala)4(H2O)]SO4.3H2O (2a)) showed no 
cytotoxicity between 0.01-10 µM in the Chang liver cell lines tested but showed cytotoxicity 
in C2C12 muscle cell lines. In 3T3-L1 both VOSO4 and [VO(ala)4(H2O)]SO4.3H2O (2a) 
showed no cytotoxicity below 0.01 µM but exhibited cytotocixity between 0.1-10 µM. 
Therefore the concentrations which were used for glucose uptake depended on the MTT 
results. Ideally, based on the MTT, concentrations which can give an 80% or more viability 
of cells are usually used. A concentration of 10 µM, 0.1 µM and 0.01 µM of the 
oxovanadium(IV) compounds were chosen for the Chang cell lines whilst a concentration of 
0.1 µM, 0.01 µM and 0.001 µM were used on C2C12 cell lines. Very low concentrations of 
0.001 µM, 0.0001 µM and 0.00001 µM were used on 3T3-L1 since the compounds showed 
that they were very toxic above 0.01 µM.   
 
 
Figure 3.14: Cytotoxicity results of VOSO4 and [VO(ala)4(H2O)]SO4.3H2O (2a) at 0.01 µM, 
0.1 µM and 10 µM on 3T3-L1, Chang liver and C2C12 muscle cells. The cell type is in 
parenthesis. Error bars indicate SEM (n = 3) 
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(b) Glucose uptake studies 
The results for the glucose uptake for VOSO4 and [VO(ala)4(H2O)]SO4.3H2O (2a) are 
presented in figures 3.15, 3.16 and 3.17. In the Chang liver and C2C12 muscle cell lines, the 
oxovanadium(IV) compounds (VOSO4, [VO(ala)4(H2O)]SO4.3H2O) (2a) enhanced glucose 
uptake relative to the control at concentrations of 10 µM  and 0.1 µM respectively. However 
the compounds did not surpass the effects observed for metformin, a drug commonly used in 
the treatment of type 2 diabetes.
35
 The uptake of glucose by the oxovanadium compounds in 
3T3-L1 adipocytes cells was poor most probably due to the low concentrations used.  
 
 
 
Figure 3.15: The effects of metformin (Met), vanadyl sulfate (VOSO4), 
[VO(ala)4(H2O)]SO4.3H2O (2a) at 0.001 µM, 0.0001 µM and 0.00001 µM on 3T3-L1 
glucose uptake. The basal glucose uptake is represented as 100% (Control). Error bars 
indicate SEM (n = 3), *(p<0.05) relative to the control 
 
* 
* 
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Figure 3.16: The effects of metformin (Met), vanadyl sulfate (VOSO4), 
[VO(ala)4(H2O)]SO4.3H2O (2a) at 10 µM, 0.1 µM and 0.01 µM on Chang glucose uptake. 
The basal glucose uptake is represented as 100% (Control). Error bars indicate SEM (n = 3), 
*(p<0.05) relative to the control  
 
 
 
Figure 3.17: The effects of metformin (Met), vanadyl sulfate (VOSO4), 
[VO(ala)4(H2O)]SO4.3H2O (2a) at 0.1 µM, 0.01 µM and 0.001 µM on C2C12 glucose 
uptake. The basal glucose uptake is represented as 100% (Control). Error bars indicate SEM 
(n = 3), *(p<0.05) relative to the control 
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The effect of the organic ligand in [VO(ala)4(H2O)]SO4.3H2O) makes little difference in this 
model compared with the inorganic salt, VOSO4, but would perhaps become important in an 
in vivo model when considering the lipophilicity/hydrophilicity of the vanadium 
compounds
36
. It has been shown that the intestinal cell permeability of complexed vanadium 
compounds far exceeds that of the inorganic salt (VOSO4),
37
 and that would have an 
advantage when it was to absorption of the compounds into the bloodstream. 
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CHAPTER 4 
IMIDAZOLYL-CARBOXYLIC ACID COMPLEXES OF 
OXOVANADIUM(IV) 
 
4.1 Introduction 
The use of imidazole compounds is well established in the field of medicinal chemistry, 
finding applications as anti-cancer,
1
 anti-bacterial,
2
 anti-fungal
3
 and anti-diabetic
4
 drugs, to 
name a few. The imidazole residue is one of the most versatile binding sites in proteins.
5
 
Imidazoles are extremely versatile ligands in that they are able to interact with many metal 
ions in not only synthetic environments, but also in natural systems.
6
 This study explores the 
use of imidazole derivatives as binding moiety to oxovanadium(IV) since imidazoles are 
known to play a significant role in a large variety of biological processes.
7,8
 It is therefore 
envisaged that these ligands should not pose a threat to the body once cleaved from the 
vanadium ion in vivo since these are prodrugs and the necessary metabolite is vanadium in a 
form of vanadyl or vanadate. 
                                           
N
H
N1
2
3
4
5
N
N
(a) (b)  
Figure 4.1: Basic structure of imidazole (a), and the anionic form (b) 
Imidazole is a planar, 5-membered, aromatic molecule, consisting of a trigonal nitrogen with 
two electrons in the p-orbital of the N-1 “pyrrole” nitrogen. At position 3 (N-3), a 
heterocyclic, “imino” nitrogen contains a lone pair of electrons in a hybrid orbital and a 
single electron in the p-orbital. The electrons in the unhybridised p-orbital of N-1 form part of 
the aromatic sextet.
9
 The N-1 electrons are not available for bond formation since the 
aromaticity of the imidazole would be compromised. However, if deprotonation were to 
occur, a lone pair of electrons would be available for bonding and it would potentially be a 
bridging ligand in this form (see figure 4.1). Alkylation of the 1-position should increase the 
basicity of the imidazole nitrogen and therefore result in a stable coordination mode of 
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(N,COO‾)-donor moiety. The presence of an alkyl group may also help to increase the 
lipophilicity of the overall complex, which is one of the requirements for a candidate oral 
drug. It is envisaged that the less basic nature of imidazoles, unlike the amine function in 
amino acids, would results in the coordination of the imidazolyl-carboxylate moiety in the 
requisite pH range thus preventing the early hydrolysis experienced with amino acids.  
The syntheses and characterization of the oxovanadium(IV) complexes with imidazole-4-
carboxylic acid, imidazole-2-carboxylic acid and 1-methylimidazole-2-carboxylic acid as 
coordinating ligands is presented. The stability constants for the complexation of 
oxovanadium(IV) to these ligands were determined. The vanadium species distribution plots 
as a function of pH are also presented. The anti-diabetic potential of these complexes has also 
been investigated via the in vitro glucose assay using 3T3-L1 adipocytes, C2C12 muscle cells 
and Chang liver cells. 
 
4.2 Experimental 
4.2.1 Reagents 
Vanadyl sulfate hydrate was obtained from BDH Limited (England).  Methylimidazole (99%) 
and imidazole-4-carboxylic acid (98%) were obtained from Sigma-Aldrich (USA).  
Imidazole-2-carboxaldehyde (97%) was obtained from Fluka (USA). All solvents were 
obtained from Merck Chemicals (SA) and were of reagent grade and used without further 
purification. Other reagent grade chemicals were also obtained from commercial sources and 
used as received. 
4.2.2 Preparative work 
(a) 1-Methylimidazole-2-carboxaldehyde  
1-Methylimidazole-2-carboxaldehyde was prepared according to a literature method.
10-12
 To a 
suspension of 1-methylimidazole (2.20 g, 0.020 mol) in dry diethylether (50 mL) was added 
2.5 M butyllithium (8.40 ml, 0.021 mol) at -78 C. After stirring for an hour, DMF (2.33 ml, 
0.030 mol) was added and this solution stirred overnight. After completion of the reaction, 2 
mL of water was added followed by 15 mL of 4 N HCl. The aqueous layer was made basic 
by addition of potassium carbonate following which; the product was extracted into 
chloroform. This organic layer was concentrated and the product was distilled at 3.0x10
-1 
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mBar and 80 
o
C to yield a brownish crystalline solid after cooling. Yield: 76.1%. δH (NMR 
400MHz, CDCl3):  4.03 (3H, NCH3), 7.16-7.27 (2H, Im-H), 9.81 (1H, CHO);  δC NMR (400 
MHz, CDCl3): 35.20, 127.69, 131.74, 144.00, 182.37. IR ν(KBr): 3108(m), 2956(m), 
2835(m), 1671(s), 1532(w), 1509(m), 1479(m), 1380(s), 1330(s), 1289(s), 1218(m), 1150(m), 
1077(m), 920(s), 766(s), 682(s) cm
-1
 Anal. Calc. (found) for C5H6N2O (110.11): C, 54.54 
(54.25); H, 5.49 (5.65); N, 25.44 (25.19)%. 
(b) Imidazole-2-carboxylic acid.H2O (Im2COOH) 
 An aqueous 30% H2O2 (10 g) was added dropwise to a stirred solution of imidazole-2-
carboxaldehyde (2.88 g, 0.030 mol) in water (10 ml). The reaction was allowed to proceed at 
room temperature for 72 hours, following which the water was removed in vacuo at room 
temperature to afford a white crystalline solid. This solid was washed with a stirred mixture 
of diethylether/water (4:1) to remove the excess peroxide. Note: heating causes 
decarboxylation. Yield: 97.5%. Mp = 156-158 
o
C. δH (400 MHz, D2O): 7.56 (2H, s, Im-H); δC 
(400 MHz, D2O): 158.86, 141.02, 120.49. IR ν(KBr): 3392(m), 3124(m), 2861(m), 1618(s), 
1502(m), 1462(m), 1421(s), 1388(s), 1322(m), 1108(s), 925(s), 910(s), 819(m), 797(s), 
774(m) cm
-1
. Anal. Calc. (found) for C4H6N2O3 (130.11); C, 36.92 (37.18); H, 4.65 (4.94); N, 
21.53 (21.47)%.  
(c) 1-Methylimidazole-2-carboxylic acid.H2O (MeIm2COOH) 
The procedure followed that of Im2COOH above except that 1-methylimidazole-2-
carboxyaldehyde was used and the yield was quantitative after the removal of water under 
high vacuum (no washing with diethylether/water was necessary). Note: heating causes 
decarboxylation. Yield: 100%. Mp = 99-101 
o
C. δH (400 MHz, D2O): 7.42, 7.39 (2H, s, Im-
H) and 4.08 ppm (3H, s, NCH3); δC (400 MHz, D2O): 158.67, 139.68, 125.83, 118.46, 36.73. 
IR ν (KBr): 3347(m) 3119(m), 2663(w), 1641(s), 1683(m), 1507(s), 1449(m), 1388(s), 
1338(s), 1285(s), 1173(m), 1123(s), 961(m) 910(m), 776(s), 685(s) cm
-1
. Anal. Calc. (found) 
for C5H8N2O3 (144.12); C, 41.67 (41.28); H, 5.59 (5.23); N, 19.44 (19.12)%.  
(d) VO(im4COO)2.H2O (2a) 
This complex was prepared according to a literature method but with slight modifications.
13
 
To a stirred aqueous solution of Im4COOH (0.254 g, 2.26 mmol), was added 10% TMAOH 
(1.04 ml, 1.13 mmol). To this solution was added aqueous VOCl2 (1.13 mmol), prepared by 
the reaction of VOSO4 with BaCl2. The reaction was allowed to stir overnight, following 
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which the light blue precipitate was collected, washed with methanol and ether and dried in 
an oven at 100 
o
C. Yield: 64.6%. Mp > 300 ºC. IR ν (neat): 3129(m), 2992(m), 2856(m), 
1606(s), 1573(s), 1499(m), 1439(m), 1356(s), 1209(m), 1080(m), 1012(m), 981(s), 878(m), 
819(s), 780(s) cm
-1
. Anal. Calc. (found) for C8H8N4O6V (307.11); C, 31.29 (31.20); H, 2.63 
(2.67); N, 18.24 (18.14)%. UV/Vis (solid reflectance), λmax  (nm): 339 , 570 , 712. 
(e) VO(im2COO)2.H2O (2b) 
This complex was prepared in the same manner as 2a, except that an aqueous solution of 
VOSO4 was added to the ligand solution instead of aqueous VOCl2.  Yield: 69.9%. Mp > 300 
ºC. IR ν (neat): 3448(m), 3129(w), 3008(m), 2906(m), 1625(s), 1558(m), 1487(m), 1398(s), 
1338(m), 1277(m), 1171(m), 1112(s), 984(s), 908(m), 829(m), 769(s), 658(s) cm
-1
. Anal. 
Calc. (found) for C8H8N4O6V (307.11); C, 31.29 (31.21); H, 2.63 (2.53); N, 18.24 (18.07)%. 
UV/Vis (solid reflectance), λmax   (nm): 333, 559, 715. 
(f) VO(MeIm2COO)2.H2O (2c) 
This complex was prepared similarly to 2a. However, upon stirring overnight a blue 
precipitate did not form. The blue solution was then allowed to stand for 24 hours and a light 
blue precipitate formed, which was filtered and washed with methanol and then ether and 
dried in an oven at 100 
o
C. Yield: 62.3%. Mp = 218-220 ºC. IR ν (neat): 3134 (m), 1628(s), 
1487(s), 1426(s), 1327(s), 1286(m), 1180(s), 1166(s), 963(s), 837(m), 797(s), 769(s), 698(s) 
cm
-1
. Anal. Calc. (found) for C10H12N4O6V (335.17); C, 35.83 (36.01); H, 3.61 (3.47); N, 
16.72 (16.67)%. UV/Vis (solid reflectance), λmax  (nm): 352, 578, 718. 
4.2.3 Potentiometric studies 
The protonation and stability constants for the ligands and oxovanadium(IV) complexes were 
determined by potentiometric acid/base titrations as explained in chapter 3. The following 
hydrolysis model of a vanadyl system was included in the model; [VO(OH)3]‾ (logβ10-3 = -
18.0) and [(VO)2(OH)5]‾ (logβ20-5 = -22.0)  while [VO(OH)]
+
 (logβ10-1 = -5.94) and 
[(VO)2(OH)2]
2+
 (logβ20-2 = -6.95) were not used.
14
 The concentration stability constants βpqr = 
[MpLqHr]/[M]
p
[L]
q
[H]
r
 were calculated by using the computer program HYPERQUAD.
15
  
The final values of the constants were obtained from an average of eight independent 
titrations using an average of around 500 data points in total for each refinement.  
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4.3 Results and discussion 
4.3.1 Synthesis and general considerations 
The synthesis of 1-methylimidazole-2-carboxaldehyde was carried out under argon and in dry 
diethylether. The presence of oxygen and water reduce the yield of 1-methylimidazole-2-
carboxaldehyde since butylithium is deactivated. Care must be taken to maintain the 
temperature at not more than -50 
o
C as higher temperatures also deactivate the butylithium. 
The 1-methylimidazole-2-carboxaldehyde decomposes via decarboxylation if it stays for 
more than one week at room temperature before it is converted to 1-methylimidazole-2-
carboxylic acid. The 1-methylimidazole-2-carboxylic acid and imidazole-2-carboxylic acid 
were prepared from the corresponding imidazole-2-carboxaldehydes by the hydrogen 
peroxide facilitated oxidation in water. This reaction requires no heating and water was the 
only by-product of oxidation, making it an environmentally friendly option. The only 
purification necessary was the removal of residual water in vacuo, at room temperature for 1-
methylimidazole-2-carboxylic acid yielding a quantitative product but imidazole-2-
carboxylic acid crystallized out with a mole equivalent of hydrogen peroxide. This was 
removed by washing with diethylether to prevent the oxidation of vanadium(IV) to 
vanadium(V) by the peroxide during the synthesis of the complexes.  The purity of the 
ligands was ascertained by elemental analysis and NMR characterization. 
O
O
OH
a b
N
N
N
N
N
N
 
Scheme 4.1: Synthesis of 1-methylimidazole-2-carboxylic acid. a. Butyllithium, DMF, 
diethylether. b. H2O2, water  
The complexes were synthesized by addition of an aqueous vanadyl chloride or vanadyl 
sulfate solution to an aqueous solution of the corresponding ligand in a 1:2 molar ratio in the 
presence of a base. There was no hydrolysis products observed. Attempts to synthesize 2a 
and 2c using VOSO4 instead of VOCl2 yielded impurities of sulfates which could not be 
washed away with water. The complexes which precipitated out of solution were easily 
collected by filtration. The compounds (2a-c) are slightly soluble in water and tend to 
decompose in organic solvents, such as acetonitrile, alcohols and DMF, upon dissolution at 
elevated temperatures and hence cryatal growth has been a challenge. 
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Figure 4.2: Chemical structures of [VO(im4COO)2] (2a), [VO(im2COO)2] (2b) and 
[VO(MeIm2COO)2] (2c) 
 
4.3.2 Spectroscopic characterization 
The formation of the aldehyde in 1-methylimidazole-2-carboxaldehyde was confirmed by the 
appearance of the peak at 9.65 ppm in the MNR spectrum of this compound (see figure 
4.4(A)). The confirmation of the oxidation of imidazole-2-carboxaldehydes to imidazole-2-
carboxylic acids was exhibited by the disappearance of the aldehyde peak at 9.7-9.8 ppm in 
the NMR spectra as depicted by figures 4.3(A) and 4.3(B).   
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Figure 4.3: 
1
H NMR spectra of imidazole-2-carboxaldehyde (A) and imidazole-2-carboxylic 
acid (B) 
   
(B) 
(A) 
(A) 
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Figure 4.4: 
1
H NMR spectra of 1-methylimidazole-2-carboxaldehyde (A) and 1-
methylimidazole-2-carboxylic acid (B) 
 
(B) 
(A) 
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In the IR spectra of the complexes (2a-c) there are strong absorption bands at 981, 984 and 
963 cm
-1 
respectively, which are assigned to the V=O stretch and are within the range 930-
1030 cm
-1  
reported in the literature
16
. The IR spectra for the ligands were also compared with 
those of their corresponding complexes and major shifts were observed as shown in figures 
4.5, 4.6 and 4.7. In imidazole ring systems, the (C=N) is usually observed at about 1650 cm-
1
.
 17
 The coordination-induced shift of this stretching frequency from 1618-1641 cm
-1
 in the 
free ligands to 1606-1628 cm
-1
 in the complexes was observed, signifying that coordination 
occurred through the imidazolyl nitrogen.
18
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Figure 4.5: The IR spectra of im4COOH and VO(im4COO)2 
ʋ(V=O) 
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Figure 4.6: The IR spectra of im2COOH and VO(im2COO)2  
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Figure 4.7: The IR spectra of Meim2COOH and VO(Meim2COO)2 
ʋ(V=O) 
ʋ(V=O) 
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The square-pyramidal oxovanadium(IV) complexes typically display three low intensity d-d 
transitions in the range of 330-1000 nm
19
. The b2→a1, b2→b1 and b2→e transitions fall in the 
ranges 332-362 nm, 555-593 nm and 700-720 nm respectively (see figure 4.8).  
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Figure 4.8: UV-vis spectra of VO(im4COO)2, VO(im2COO)2 and VO(Meim2COO)2 
 
4.3.3 pH-metric solution speciation studies 
The equilibrium constants were derived by best-fitting of the experimental data with a 
chemical model of the equilibrium system (see figure 4.9). The experimental data points with 
larger residuals were removed during the refinement. Data from the regions in which there 
was no complex formation and in a region in which complex formation was essentially 
complete were excluded from the calculations since they contributed no information 
regarding the formation constants. They only represented the effects of dilution and their 
inclusion adversely affected the quality of the fit. 
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Figure 4.9: Titration and fitted curves of VO-imidazole-2-carboxylic acid. Experimental 
points are represented by blue squares and the calculated least-squares fit by the red dotted 
line. The other lines represent the species (not specified) 
 
The protonation (logK) and oxovanadium complex formation (logβ) constants are listed in 
Table 4.1 together with standard deviations. The ligands exhibit two protonation processes in 
the pH range 2-11 for the carboxylate and imidazole groups respectively. The logK2 values 
for the protonation of imidazole in all cases, imidazole-4-carboxylic acid (6.13), imidazole-2-
carboxylic acid (6.44) and 1-methylimidazole-2-carboxylic acid (6.75), are lower than those 
of free imidazole (6.95)
21
 and free 1-methylimidazole (7.20)
22
 respectively. The latter is 
slightly more basic probably due to the presence of the electron releasing methyl substituent. 
The low logK1 values (2.70, 2.72 and 1.29) for imidazole-4-carboxylic acid, imidazole-2-
carboxylic acid and 1-methylimidazole-2-carboxylic acid respectively suggest internal 
hydrogen bonding between the protonated imidazole and a carboxylate. This suggests that 
these ligands exist in a zwitterion form such as that observed for simple amino acids in water. 
The pyrole sites in imidazole-4-carboxylic acid and imidazole-2-carboxylic acid do not 
dissociate in the pH range measured. The proposed interactions of these ligands with the acid 
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in aqueous solutions are represented by Scheme 4.2. The ligand imidazole-2-carboxylic acid 
shows similar interactions and stability with vanadyl as imidazole-4-carboxylic acid. 
 
Table 4.1: Protonation (logK) and stability (logβ) constants for the VIVO-(imidazole,COO) 
systems at I = 0.10 M TMACl and T = 25.0±0.1
o
C. Comparison with other V
IV
O-
(imidazole/pyridine,COO) systems is also presented. Standard deviations (errors in the last 
digit) are reported in parenthesis 
 
 
Reaction 
                    Ligand  
Im-4-
COOH 
Im-2-
COOH 
Meim-2-
COOH 
Im-4-acetic 
acid*[21] 
Picolinic 
acid*[22] 
pK1 LH2
+
  H
+
 + LH 2.70(3) 2.72(3) 1.29(12) 3.19(1) ~1 
pK2 LH  H
+
 + L
-
 6.13(1) 6.44(2) 6.75(3) 7.34(1) 5.19(2) 
logβ110 VO
2+
 + L
-
   [VO(L)]
+
 7.11(2) 7.53(3) 9.84(6) 6.10(1) 6.66(2) 
logβ111 VO
2+
 + H
+
 + L
-
   [VO(LH)]
2+
 - - 14.85(7) 11.04(4) - 
logβ120 VO
2+
 + 2L
-
  [VO(L)2] 11.38(8) 11.62(6) 15.49(9) 10.70(1) 12.11(2) 
LH2
+
=imH4COOH
+
, imH2COOH
+
 or MeimH2COOH
+
; LH=im4COOH, im2COOH or 
Meim2COOH; L
-
=im4COO
-
, im2COO
-
 or Meim2COO
-
. *T = 25.0±0.1
 o
C and I = 0.20 M 
KCl using ca 0.2 M KOH as titrant 
                   
                   
Scheme 4.2: The protonation steps for im4COOH (A) and Meim2COOH (B) 
 
(B) 
(A) 
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Figure 4.10: Species distribution as a function of pH for imidazole-4-carboxylic acid 
 
 
Figure 4.11: Species distribution as a function of pH for 1-methylimidazole-2-carboxylic 
acid 
The species distribution as a function of pH for imidazole-4-carboxylic acid and 1-
methylimidazole-2-carboxylic acid are shown in figures 4.10 and 4.11. The imidazole-4-
0 4 8 12 
pH 
0 
20 
40 
60 
80 
100 
Meim2COO
-
 
Meim2COOH 
 
  
MeimH2COOH
+
 
%
 f
o
rm
at
io
n
 r
el
at
iv
e 
to
 M
ei
m
2
C
O
O
H
 
M
ei
m
2
C
O
O
H
 
0 2 4 6 8 
pH 
0 
20 
40 
60 
80 
100 
%
 f
o
rm
at
io
n
 r
el
at
iv
e 
to
  
im
4
C
O
O
H
 
im4COO- 
im4COOH 
 
  imH4COOH+ 
76 
 
carboxylic acid speciation shows that at pH 2.70 imidazole-4-carboxylic acid is 50% 
protonated (i.e. the carboxyl oxygen is protonated) and at pH 6.13 the mildly basic imidazole 
nitrogen is 50% protonated. The pKa for these weak acids corresponds to the pH at half 
neutralization, i.e. where the concentration of the undissociated acid mirrors the concentration 
of the acid.  
The proposed interactions of these ligands in aqueous solutions with oxovanadium(IV) are  
represented by Scheme 4.3. The ligand imidazole-2-carboxylic acid shows similar 
interactions and stability with vanadyl as imidazole-4-carboxylic acid. The species 
distribution diagrams are represented by Figures 4.12, 4.13 and 4.14 for the (V
IV
O)-
imidazole-4-carboxylic acid, (V
IV
O)-imidazole-2-carboxylic acid and (V
IV
O)-1-
methylimidazole-2-carboxylic acid systems, respectively. 
 
Scheme 4.3: The stepwise formation of oxovanadium(IV) complexes formed with imidazole-
4-carboxylic acid and 1-methylimidazole-2-carboxylic acid 
The ligands adopt bidentate chelation. The first binding constants could be calculated with a 
1:1 metal-to-ligand ratio and precipitation due to the formation of hydrolysis products was 
observed for titrations with a 1:2 metal-to-ligand ratio. Extensive V
IV
O complexation was 
obtained with a high ligand excess (10-fold), allowing for the determination of the second 
binding constant. The fitting of the titration data supports the formation of monomeric 
[VOL]+ and [VOL2] species as well as [VOLH]
2+ for 1-methylimidazole-2-carboxylic acid. 
Similarly to the VO
2+
-glycine and VO
2+
-ʟ-alanine systems, the hydroxo binding 
([VOL2(OH)]
_
) could not be fitted in both models while the assumption of the binary 
hydroxyl species  [(VO)2(OH)5]
-
 as well as [VO(OH)3]- in highly basic solutions fitted well.  
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Figure 4.12: Speciation curves for complexes formed in the (V
IV
O)-imidazole-4-carboxylic 
acid system (M:L ratio is 1:4)  
 
Figure 4.13: Speciation curves for complexes formed in the (V
IV
O)-imidazole-2-carboxylic 
acid system (M:L ratio is 1:4)  
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Figure 4.14: Speciation curves for complexes formed in the (V
IV
O)-1-methylimidazole-2-
carboxylic acid system (M:L ratio is 1:4) 
 
The overall stability constant for the (V
IV
O)-N-methylimidazole-2-carboxylic acid system 
(log β120 =15.49(9)) is far larger than that for imidazole-4-carboxylic acid system (log β12 
=11.38(8)) and imidazole-2-carboxylic acid system (log β12 =11.62(6)). This can be explained 
by the fact that the imidazole nitrogen in 1-methylimidazole-2-carboxylic acid is more basic. 
However, the overall stability constant of the (V
IV
O)-imidazole-4-carboxylic acid and 
(V
IV
O)-imidazole-2-carboxylic acid systems are comparable to that of (V
IV
O)-imidazole-4-
acetic acid (im-4-acetic acid) (log β120 =10.70(1))
22 
and that with mildly basic pyridine 
nitrogen of picolinic acid (log β120 =12.11(2))
23
 (see table 4.1) intimating that inclusion of an 
electron donating group in the 1 position of imidazole is important to effect stability. In 
addition, six-membered ring chelate formation in the (V
IV
O)-imidazole-4-acetic acid system 
results in weaker binding compared with five-membered ring systems studied here. 
For the 1-methylimidazole-2-carboxylic acid system, however, the coordination of a 
protonated ligand is observed at low pH with log β111=14.84(7). This suggests strong binding 
and the possibility of a symmetrically chelating carboxylate ion, with the imidazole nitrogen 
protonated (see Schemes 4.2 and 4.3). For the formation of monomeric [VOL]+ and [VOL2] 
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species, the very acidic carboxylic acid groups interact with VO
2+
 at very low pH and the 
mildly basic imidazole is able to interact with vanadyl at relatively higher pH. The result is 
the stabilization of these oxovanadium(IV) complex systems in the relevant biological pH 
range.  
4.3.4 Biological studies 
(a) Cytotoxicity 
To ascertain if any of the vanadium compounds (VO(MeIm2COO)2, VO(im2COO)2, 
VO(im4COO)2) were toxic, MTT assays were performed on each of the cell lines to 
determine cell viability. Figure 4.15 shows the results of the cytotoxicity test. Most of the 
compounds are toxic at concentrations above 0.1 µM on 3T3-L1 cell lines and only the 
vanadyl sulfate is non toxic on Chang cells at concentrations 0.01-10 µM. Even at a low 
concentration of 0.01 M , VO(im4COO)2 and VO(Meim2COO)2 are still toxic on 3T3-L1 
adipocytes. However, the greatest cell viability is achieved on 3T3-L1 adipocytes by 
VO(im2COO)2 at a concentration of 0.001 M. 
 
 
Figure 4.15: Cell viability of VOSO4, VO(im4COO)2 (2a), VO(im2COO)2 (2b) and, 
VO(MeIm2COO)2 (2c) at 0.01 µM, 0.1 µM and 10 µM on 3T3-L1, Chang and C2C12 cells. 
The cell type is in parenthesis. Error bars indicate SEM (n = 3) 
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The concentrations which were used for glucose uptake depended on the MTT results. At 
concentrations 10 µM, 0.1 µM and 0.01 µM the compounds were not cytotoxic on Chang cell 
lines but on C2C12 only a concentration of 10 µM was cytotoxic, therefore concentrations of 
0.1 µM, 0.01 µM and 0.001 µM were used for the glucose uptake studies. Very low 
concentrations of 0.001, 0.0001 and 0.00001 µM were used on 3T3-L1 for glucose uptake 
since the compounds showed that they were very toxic at 0.01 µM.  
(b) Glucose uptake studies 
The results of glucose uptake are presented in figures 4.16, 4.17 and 4.18. As depicted in 
figure 4.17, the oxovandium(IV) compounds (VOSO4, VO(Meim2COO)2, VO(im4COO)2) 
enhanced glucose uptake at a concentration of 10 µM on the Chang liver cells, either 
equaling or surpassing the effects observed for metformin, a first-line drug commonly used in 
the treatment of type 2 diabetes particularly in overweight and obese people.
24
 The uptake of 
glucose by the oxovanadium compounds in 3T3-L1 muscle cells was poor most probably due 
to the low concentrations used. Out of the three oxovanadium(IV) complexes, VO(im4COO)2 
(2a) showed the best glucose uptake at concentrations 0.001 µM on 3T3-L1 adipocytes, 10 
µM on Chang liver cells and 0.1 µM on C2C12 muscle cells. At present there is no known 
special explanation attributed to the unique properties of VO(im4COO)2 on glucose uptake 
since the three compounds are very similar. The glucose uptake of all the three complexes are 
well comparable to the effect of oxovanadium(IV) complexes of Schiff base ligands and 
hydroxyphenyimidazolines on Chang liver cells, but they also showed enhanced glucose 
uptake on 3T3-L1 adipocytes and C2C12 muscle cells in contrast to the compounds studied 
here.
25,26
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Figure 4.16: The effects of metformin (Met),  VOSO4, VO(im4COO)2 (2a), VO(im2COO)2 
(2b) and VO(MeIm2COO)2 (2c) at 0.001 µM, 0.0001 µM and 0.00001 µM on 3T3-L1 
glucose uptake. The basal glucose uptake is represented as 100% (Control). Error bars 
indicate SEM (n = 3). *p < 0.05 relative to the control 
 
 
Figure 4.17: The effects of metformin (Met),  VOSO4, VO(im4COO)2 (2a), VO(im2COO)2 
(2b), and VO(MeIm2COO)2 (2c) at 10 µM, 0.1 µM and 0.01 µM on Chang glucose uptake. 
The basal glucose uptake, is represented as 100% (Control). Error bars indicate SEM (n = 3). 
*p < 0.05 relative to the control 
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Figure 4.18: The effects of metformin (Met),  VOSO4, VO(im4COO)2 (2a) VO(im2COO)2 
(2b), and VO(Meim2COO)2 (2c), at 0.1 µM, 0.01 µM and 0.001 µM on C2C12 glucose 
uptake. The basal glucose uptake is represented as 100% (Control). Error bars indicate SEM 
(n = 3). *p < 0.05 relative to the control 
Although the in vitro model used may have certain shortcomings, in that it does not exactly 
replicate in vivo conditions
25
, it does provide a simple and ethical platform for the rapid 
assessment of new complexes. It can be seen that the vanadium salt (VOSO4) almost always 
performs better than the complexes presented in chapters 3 and 4 and this is in agreement 
with the fact that these are prodrugs. Under physiological condition, the ligands would 
dissociate and make vanadium available in a form of vanadyl or vanadate which is the active 
species, hence the lower activity under in vitro conditions compared with VOSO4 which is 
readily convertible to vanadate under the conditions employed. Therefore, it can be 
concluded that the glucose assay may not necessarily be the best platform for screening the 
candidate vanadium anti-diabetic drugs despite the ethical nature of their practice.  
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CHAPTER 5 
CONCLUSIONS AND FUTURE WORK 
 
5.1 Conclusions 
Two novel oxovanadium(IV) complexes of glycine and ʟ-alanine were successfully 
synthesized and partially characterised. The spectroscopic studies suggested that the amino 
acids coordinate to the oxovanadium through the amine-nitrogen and the geometry suggested 
by the electronic spectra is distorted octahedral. The oxovanadium(IV) complex of glycine, 
[VO(gly)4(CH3CH2OH)]SO4, was isolated but was not very pure and structural 
characterization was tentative, and as a result biological studies were not done. The 
oxovanadium(IV) complex of ʟ-alanine, [VO(ala)4(H2O)]SO4.3H2O, was isolated and the 
glucose uptake effect was investigated using 3T3-L1, Chang liver and C2C12 muscle cells at 
various concentrations. The compound had significant glucose uptake on Chang liver cells 
only at a concentration of 0.1-10 µM whilst in the C2C12 muscle and 3T3-L1 cells the 
compound showed little anti-hyperglycemic activities due to the low concentrations used as a 
result of cytotoxicity. The acidity constants of glycine and ʟ-alanine, and the stability 
constants of their corresponding oxovanadium(IV) complexes were determined by 
potentiometric acid-base titrations, but there is contradiction in the of coordination of these 
simple amino acids to V
IV
O from evidence of solid state and solution studies. 
Three imidazole derivatives and their corresponding oxovanadium(IV) complexes were 
successfully synthesized and characterized. However, the isolated solid state complexes lack 
water-solubility which is one of the desired properties of these glucose-lowering compounds. 
The electronic spectroscopic studies of the oxovanadium(IV) complexes of 1-
methylimidazole-2-carboxylic acid ([VO(Meim2COO)2]), imidazole-2-carboxylic acid 
([VO(im2COO)2]) and imidazole-4-carboxylic acid ([VO(im4COO)2]) suggest that a square 
pyramidal geometry can be tentatively assigned and confirmation of the structures by X-ray 
crystallography was not done as crystals could not be developed during the course of the 
study. The (imidazole,COO
_
)
 
donor set has been shown to stabilize V
IV
O through bidentate 
coordination. The binding constants for the 2-substituted imidazole indicate a stronger 
binding mode for this donor set. The calculations for the species distribution in the 
experimental pH range showed that the neutral bis-coordinated complexes are dominant over 
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the biological pH range. In this system the solid state compounds isolated agreed well with 
the solution model with respect to coordination.  
All complexes increased glucose utilization in Chang liver and to some extent in C2C12 
muscle cells over basal values. Glucose uptake was not significant in 3T3-L1 adipocytes due 
to the low concentrations used. However, the in vitro results cannot give reliable observations 
because it has got so many limitations and therefore in vivo studies on these compounds are 
recommended. 
 
5.2 Suggestions for future work 
Since the oxovanadium(IV)-imidazole derivatives complexes are not soluble in water, 
modification of the 1-position of the imidazole by introducing an alcohol group, e.g. ethanol, 
that can improve the physicochemical properties of this (imidazole,COO) moiety. These 
complexes could be investigated further via an in vivo model using the Zucker fatty rats since 
the in vitro glucose uptake assay does not provide adequate information.
 
The Zucker fatty rat 
is a model for type II diabetes.
1
 The investigation would include, determination of plasma 
glucose levels at certain times after administration of vanadium compounds, as well as the 
determination of plasma and tissue vanadium concentrations, as well as toxicity studies. 
The study of the vanadium distribution in tissue is important since the biological action of the 
complexes on target organs may be controlled by varying physicochemical properties of the 
organic ligand.
2
 This analysis can be done by sacrificing the mice after administration of the 
complexes and then removing the selected organs for washing and digestion and then finally 
analysing for vanadium concentrations using atomic absorption spectrometry or inductively 
coupled plasma mass spectrometer (ICP-MS). 
After the biological administration of the vanadium complexes, the complexes may dissociate 
due to vanadium complexation reactions with the vast number of biological ligands present. 
To illustrate that the synthesized vanadium complexes convert to the active metabolites for 
glucose level lowering it is necessary to investigate the species that are present in the blood 
system. Due to the complex matrix of blood and the relatively low concentration of the 
vanadium in blood, a hyphenated reversed phase chromatographic system (HPLC) coupled to 
the highly sensitive inductively coupled plasma mass spectrometer (ICP-MS) as detector 
could be used. In this manner speciation of vanadium complexes in blood can be achieved.   
87 
 
The glucose stimulated insulin secretion (GSIS) studies can also be carried out using these 
vanadium complexes. This would render the vanadium-based anti-diabetic drugs useful in 
cases where type 2 diabetics cease to produce sufficient insulin. Initial studies by our group 
revealed that vanadium may possibly stimulate the secretion of insulin (i.e. an alternate 
pathway to the accepted pathway). The amount of insulin secretion would be quantified using 
the 
125
I radioimmunoassay (Rat Insulin RIA kit).
3
 Pancreatic cells (INS-1) would be seeded 
and incubated in RPMI+glutamax media containing glucose concentrations of 11.1 mM and 
33.3 mM. This media would then replaced with media containing low (3.33 mM) and high 
(16.3 mM) glucose concentrations as well as the oxovanadium compounds. The insulin 
secreted under basal (3.3 mM) and stimulated (16.3 mM) conditions can then be quantified 
using the radioimmunoassay,
3
 and the stimulatory index can be calculated.  
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